ESTRO
Rue Martin V, 40
1200 Brussels
Belgium
Tel.: +32 2 775 93 40
Fax: +32 2 779 54 94
info@estro.org
WWW.ESTRO.ORG
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Page</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>EDITORIAL</td>
</tr>
<tr>
<td>5</td>
<td>MISSION</td>
</tr>
<tr>
<td>7</td>
<td>MEMBERSHIP</td>
</tr>
<tr>
<td>21</td>
<td>SCIENCE DISSEMINATION</td>
</tr>
<tr>
<td>75</td>
<td>ESTRO SCHOOL</td>
</tr>
<tr>
<td>93</td>
<td>PUBLIC AFFAIRS</td>
</tr>
<tr>
<td>107</td>
<td>THE ESTRO CANCER FOUNDATION</td>
</tr>
<tr>
<td>115</td>
<td>FINANCIAL REPORT</td>
</tr>
<tr>
<td>119</td>
<td>ANNEX</td>
</tr>
</tbody>
</table>

## MEMBERSHIP
- Profile of ESTRO members | 8
- Main benefits of membership | 10
- Structured and diversified membership categories | 11
- Membership categories under the spotlight | 12
- Strategic milestone | 19

## SCIENCE DISSEMINATION
- Meetings | 22
- Publications | 48
- ESTRO and research | 66
- Guidelines | 72

## ESTRO SCHOOL
- Live courses | 77
- Pre-meeting courses | 83
- E-learning | 85
- Strategic milestone | 90

## PUBLIC AFFAIRS
- Health Economics in Radiation Oncology (HERO) | 94
- National societies | 96
- Patients | 98
- Industry | 99
- Members | 99
- Other oncology societies | 100
- Radiation Oncology Safety and Quality Committee (ROSCQ) | 103

## THE ESTRO CANCER FOUNDATION
- The Marie Curie legacy campaign | 109
- Super Run | 113
Another year has flown by and what a busy year it was for ESTRO. This annual report gives you a strong sense of the Society’s persistence in expanding and improving its array of activities in 2017, highlighting many of the remarkable achievements from the year. I hope you enjoy reading it.

It is striking that yet again ESTRO membership has increased, a clear indication that we deliver quality educational and scientific programmes valued by professionals in radiation oncology. Another contributing factor is the attractiveness of the structured and diversified membership categories that we offer. Of significance here is the new membership model, the ESTRO RTT Alliance, which launched in 2017. The Alliance aims to achieve better recognition of the radiation therapists’ (RTT) profession at both the political level of oncopolitics and in the treatment of cancer patients.

Our annual conference, ESTRO 36, which was held in Vienna, Austria, in May 2017, confirmed the meeting as the premier platform for networking and finding state-of-the-art and breaking news on radiation oncology. We again saw a steady increase in participation across the board at both individual and industry level. ESTRO also collaborated with other oncology societies on topical/organ-based multidisciplinary meetings, including EMUC, ICHNO and ELCC, as well as on non-organ-based meetings, such as the European Cancer Congress. All these meetings underscore interdisciplinary and multidisciplinary approaches to improving cancer care. Closer to home, ESTRO continues to encourage and facilitate scientific and professional networking opportunities within ESTRO sub-specialties via workshops. Workshops held by our physicists and brachytherapists were particularly successful.

The Society’s flagship journal, Radiotherapy & Oncology, welcomed six new editors in 2017. It was also the first year in which we witnessed the contribution of our three new open-access journals: Clinical and Translational Radiation Oncology (ctRO); Physics and Imaging for Radiation Oncology (phiRO); and Technical Innovations and Patient Support in Radiation Oncology (tipsRO).

You will find out more about these exciting developments and other ESTRO publications in this annual report.

The ESTRO School’s catalogue of courses is continuously developed to maintain its quality, ensuring that the courses meet the needs of ESTRO members and incorporate the latest technology. One notable example is the use of the FALCON platform in not only live, blended and e-learning courses, but also in other activities such as research and the development of guidelines.

The net of ESTRO’s public affairs activities is steadily being cast wider, ensuring that stakeholders are empowered with the necessary information to advocate for radiation oncology at the European level. The high point of these activities was towards the end of 2017 when a workshop on health economics in radiation oncology (HERO) concluded with a policy symposium at the European Parliament.

Another significant development was the ESTRO Cancer Foundation’s (ECF) launch of the Marie Curie Legacy Campaign, which pitched positive stories to the media about the 150th anniversary of Marie Curie’s birth to raise awareness with the
general public of the benefits of radiotherapy in curing cancer.

Finally, my term as President of ESTRO ends in April 2018 at our annual conference, ESTRO 37, in Barcelona, Spain. It has been an honour and privilege to serve in this capacity. I thank all our members and other stakeholders for contributing to the success and strength of our activities. I am also grateful for the cooperation and support I received in working with the Board, ESTRO governance, and the ESTRO staff.

Best wishes,

Yolande Lievens
ESTRO President

MISSION

The mission of ESTRO, a non-profit, scientific organisation, shall be to foster, in all its aspects, radiotherapy (also known as radiation oncology), clinical oncology and related subjects, including physics as applied to radiotherapy, radiation technology and radiobiology.

To fulfill its mission ESTRO will:

- Develop and promote standards of education in radiotherapy and clinical oncology
- Promote standards of practice in radiotherapy, clinical oncology and related subjects
- Stimulate the exchange of scientific knowledge in all related fields
- Strengthen the clinical specialty of radiotherapy and clinical oncology in relation to other specialties and professions involved in cancer management
- Encourage co-operation with international, regional and national societies and bodies representing radiotherapy, clinical oncology and related subjects
- Facilitate research and development in radiotherapy, clinical oncology and related subjects.
With nearly 7,300 radiation oncology professionals from across the world, the ESTRO membership is the heart of our organisation.

In 2017, ESTRO continued to attract new members and engage existing members by giving them the resources and tools they need to successfully navigate a career in radiation oncology and its related fields. From support for professional development to even greater access to scientific information, the membership programme is focused on giving members more of what they need and want.
MEMBERSHIP
PROFILE OF ESTRO MEMBERS

7,281 MEMBERS IN 2017
FIVE CONTINENTS
III COUNTRIES

GEOGRAPHICAL DISTRIBUTION OF ESTRO MEMBERS

TOP 10 MEMBER COUNTRIES
1. The Netherlands
2. Germany
3. UK
4. Italy
5. Canada
6. Belgium
7. Australia
8. Spain
9. Switzerland
10. Denmark

Two non-European countries – Australia and Canada – are in the top ten member countries.
The ESTRO community extends far beyond these professional radiation oncology disciplines, taking in a wide range of other professions. This includes professionals from:

- other medical fields related to oncology, such as surgeons, radiologists, medical oncologists, gynaecologists and urologists
- non-medical fields, such as public affairs specialists.

**BREAKDOWN OF ESTRO MEMBERS BY SPECIALTY**

- 51% radiation oncologists
- 23% medical physicists
- 11% RTT – nurses – dosimetrists
- 6% clinical oncologists
- 1% radiobiologists
- 1% industry representatives
- 2% other medical and non-medical specialties

**EVOLUTION OF MEMBERSHIP**

<table>
<thead>
<tr>
<th>Year</th>
<th>Membership</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>5,622</td>
</tr>
<tr>
<td>2014</td>
<td>5,830</td>
</tr>
<tr>
<td>2015</td>
<td>6,635</td>
</tr>
<tr>
<td>2016</td>
<td>6,742</td>
</tr>
<tr>
<td>2017</td>
<td>7,281</td>
</tr>
</tbody>
</table>

INCREASE OF 30% IN FIVE YEARS
ESTRO contributes to the day-to-day practice and career advancement of oncology professionals through the dissemination of the latest research findings and knowledge.

ESTRO offers several levels of membership, with benefits tailored to the needs of each member and their level of involvement within the Society.

The full range of ESTRO membership benefits includes:

- Belonging to a community of around 7,300 radiation oncology professionals
- Online subscription to *Radiotherapy & Oncology*, the Society’s journal
- Networking opportunities and reduced fees for attending ESTRO teaching courses, online courses, workshops and conferences
- Online access to scientific material, including event webcasts and delineation cases through the ESTRO electronic library (DOVE)
- Eligibility for grants and awards
- Eligibility for ESTRO faculties and governance positions

ESTRO contributes to the day-to-day practice and career advancement of oncology professionals through the dissemination of the latest research findings and knowledge.
**MEMBERSHIP**

7,281 MEMBERS IN 2017

66% 4,812 individual members
39% full membership
- 38% active
- 1% supporting ambassador
27% associate membership
- 21% affiliate
- 5% in training
- 1% honorary

1% 957 dual and young dual members
11 national societies

18% 1,267 institutional members
45 institutes

3% 185 corporate members
30 companies

1% 69 RTT Alliance members
9 national societies

**INDIVIDUAL MEMBERSHIP:**

- **Full membership:**
  - Active
    - €95 for one year - €170 for two consecutive years
  - Supporting ambassador
    - €250 for one year - €450 for two consecutive years
  - Emeritus

- **Associate membership:**
  - In training - €75
  - Affiliate - €55
  - Corporate representative - €55
  - Honorary

**DUAL AND YOUNG DUAL MEMBERSHIP**

**INSTITUTIONAL MEMBERSHIP**

**CORPORATE MEMBERSHIP**

**NEW IN 2017: RTT ALLIANCE**

see strategic milestone

*ALL PRICES ABOVE INCLUDE VAT*
1. Institutional membership

The institutional membership category is designed to help European hospitals, clinics or other institutions providing radiotherapy and cancer treatment to develop and support their in-house radiotherapy and oncology professionals.

This category allows institutes to pay a single fee for individual membership on behalf of their employees who can enjoy all the usual advantages of individual membership. The institutions themselves receive a range of benefits, including:

- A dedicated institutional Corner in the newsletter, with the possibility of regularly covering developments at the institution
- A dedicated institutional webpage on the ESTRO website
- Free online job postings
- A monthly ESTRO Public Affairs newsletter sent exclusively to all institutional members
- An ESTRO institutional member logo, which can be used by the institute on their website, and in scientific presentations alongside their own logo
- A free booth in the ESTRO 36 Communities Pavilion in Vienna in May 2017.

7 NEW INSTITUTIONAL MEMBERS in 2017
45 INSTITUTE MEMBERS in total (see annex p 127 for list)
1,267 EMPLOYEES SUPPORTED through this membership category
COMMUNITIES PAVILION

At ESTRO 36, the Communities Pavilion, located in the exhibition hall, worked as a networking platform for the diverse radiation oncology community, fostering exchanges about science, projects, job opportunities and mutual collaborations.

Fifteen stakeholders in the field of radiation oncology exhibited, including institutional members, national societies, and international patient and oncology associations.

The 15 stakeholders exhibiting at the ESTRO 36 Communities Pavilion were:

- Academic Medical Centre, Amsterdam
- ASCO – American Society of Clinical Oncology
- BIR – The British Institute of Radiology
- ECPC – European Cancer Patient Coalition
- EFOMP – European Federation of Organisations for Medical Physics
- EFRS – European Federation of Radiographer Societies
- EIBIR – European Institute for Biomedical Imaging Research
- Europa Uomo
- Gemelli Art – Policlinico Universitario “Agostino Gemelli”
- Greater Poland Cancer Centre
- Irish Institute of Radiography and Radiation Therapy
- Istituto Del Radio, University of Brescia
- RSRMO – Romanian Society of Radiotherapy and Medical Oncology
- University Medical Centre Utrecht
- University of Florence, Careggi Hospital.
BREAKDOWN OF THE INSTITUTIONAL MEMBERSHIP

1,267 INSTITUTIONAL MEMBERS

45 institutes
- 62% active
- 22% in training
- 13% affiliate
- 3% supporting ambassador

NEW INSTITUTIONAL MEMBERS IN 2017

BELGIUM
GZA Ziekenhuizen, Sint Augustinus – Iridium Kankernetwerk

GERMANY
Klinikum rechts der Isar, TU Munich

DENMARK
- Odense University Hospital
- Aalborg University Hospital

SWITZERLAND
Ente Ospedaliero Cantonale in Bellinzona

FRANCE
GORTEC – CHU Bretonneau – CORAD

UK
St Bartholomew’s Hospital, London

► See p 127 for the full list of institutional members.
2. Supporting ambassador members

This category is reserved for professionals in the field of radiation oncology who are strongly committed to the Society and who want to contribute to the Ambassador Solidarity Fund. The additional income generated goes towards the Ambassador Solidarity Fund.

WHO BENEFITS FROM THE AMBASSADOR SOLIDARITY FUND?
The Fund enables sponsorship of educational grants, individual membership and registrations to ESTRO courses or events to help radiation oncology professionals from European countries facing more difficult economic situations (conditions apply).

In 2017, 91 INDIVIDUALS signed up as supporting ambassadors.

IN 2017, EDUCATIONAL GRANTS AWARDED BY THE AMBASSADOR SOLIDARITY FUND HELPED:

- 6 COURSE PARTICIPANTS selected by local course organisers received a course registration and an affiliate membership
- 10 COURSE PARTICIPANTS were funded to attend an ESTRO course.

PARTICIPANTS AT ESTRO 36 - NINE APPLICANTS CURRENTLY IN TRAINING RECEIVED:

- FREE REGISTRATION
- FREE IN-TRAINING 2017 MEMBERSHIP
The younger generation is the Society’s future and therefore it is essential for ESTRO to involve our young members in all of the Society’s activities, from the more basic to the strategic. The young members include young professionals up to the age of 40.

ESTRO also continues to develop its collaborations with European societies representing young members to encourage more young radiation oncology professionals to access the Society’s activities. We also offer a dual membership tailored to these societies with a range of benefits.

**3. In-training members and young scientists**

The younger generation is the Society’s future and therefore it is essential for ESTRO to involve our young members in all of the Society’s activities, from the more basic to the strategic. The young members include young professionals up to the age of 40.

ESTRO also continues to develop its collaborations with European societies representing young members to encourage more young radiation oncology professionals to access the Society’s activities. We also offer a dual membership tailored to these societies with a range of benefits.

**BREAKDOWN OF YOUNG MEMBERS:**

- Institutional in-training members: 32%
- Individual in-training members: 45%
- Young dual members: 23% who get the same benefits as an ‘in-training member’
EXAMPLES OF THE RESPONSIBILITIES OF YOUNG ESTRO MEMBERS

THE YOUNG CORNER
in the ESTRO newsletter. Each issue contains a dedicated young section, coordinated by two young editors with news from young national societies, and young members sharing their experience through meetings or travel grants reports etc.

THE YOUNG FACEBOOK PAGE
with more than 1,600 'likes', the young Facebook page is handled by the young committee and focuses on topics of interest to young radiation oncology professionals.

THE YOUNG COMMITTEE
is composed of 11 members from all radiation oncology disciplines that are appointed by the Board and is involved at governance level. Two new members joined the young committee in 2017.

THE YOUNG TRACK
is an all-day session held during ESTRO’s annual scientific meeting, which focuses specifically on topics of interest to young professionals.
4. 2017 Joint memberships

This category can be granted to individual members who benefit from a joint membership agreement, signed on a case-by-case basis between ESTRO and a non–European national society or a European young national society active in the field of radiation oncology.

NEW

In 2017, we concluded one new dual membership agreement with the:
Iranian Society of Clinical Oncology (ISCO)

► See p 126 for a list of all dual membership agreements.

5. Corporate membership

Companies can opt for either ESTRO’s regular or gold corporate membership. Gold membership gives the right to a seat on the ESTRO corporate council, which works to facilitate collaboration and coordination between industry’s research and development activities, and the academic and scientific developments within ESTRO.

30 CORPORATE MEMBERS

- 21 regular members
- 9 gold members
The ESTRO RTT Alliance aims at playing a major role in the political arena for a better representation of RTTs on the oncopolicy scene and for an improved recognition of the profession in the treatment of cancer patients.

The aims of the ESTRO RTT Alliance are to:
- strengthen the voice of RTTs at the international level
- facilitate improved recognition and professional development of RTTs across Europe
- offer a means for RTTs within national societies to network, access information from one another and from within the ESTRO scientific and educational network
- promote cross-fertilisation of learning and ideas as well as uniting to form a critical mass of RTTs with common interests.

All the European national societies representing RTTs are invited to join the RTT Alliance: for only €15 per year, their RTT members will benefit from a network to support their career development such as:
- access to information included from the ESTRO scientific and educational communities
- a mutual exchange on best practice and experience
- a united voice of RTTs with common interests.

IN 2017, 9 NATIONAL SOCIETIES JOINED THE ESTRO RTT ALLIANCE:

- Bulgarian Society of Radiation Therapy Technicians
- Croatian Association of Radiation Technologists
- Italian Association of Radiation Therapist and Medical Physic Technologists
- Portuguese Radiation Therapists National Society
- Serbian Society of Radiotherapy Technicians
- Society of Radiation Therapy Technologists (Turkey)
- Society of Medical Radiographers (Malta)
- Society of Radiological Technology Austria
- Spanish Association of Radiotherapy and Oncology (SEOR).
SCIENCE DISSEMINATION
As well as including events organised by ESTRO, this section also covers events organised in association with other partners, and those supported by ESTRO.

1. ESTRO annual congress: ESTRO 36

_The leading platform for radiation oncology in Europe_

5-9 May 2017 | Vienna, Austria

ESTRO has a long track record of organising conferences, disseminating the latest findings and providing a platform for networking. Three years on from ESTRO 33, the annual congress was back in Vienna, Austria, attracting 5,860 participants.

**A COMPREHENSIVE PROGRAMME**

The state-of-the-art scientific programme is developed by expert members of the congress’ various scientific advisory groups, who all work on a voluntary basis. The programme covered all aspects of radiation oncology, featuring presentations from clinicians, medical physicists, radiobiologists, brachytherapists and radiation therapists.

**NETWORKING**

There were multiple opportunities to network at ESTRO 36, including at the 10,000m² exhibition space, the communities pavilion and start-up corner, and social activities such as the welcome reception, poster awards ceremony, the Super Run and the social event… Participants were also invited to the RTT meet and greet, the Physics and GEC-ESTRO assemblies, as well as the general assembly for ESTRO members.

**MANY EDUCATIONAL ACTIVITIES**

The educational programme included pre-meeting courses, teaching lectures, tumour board and contouring sessions. You can read about the educational programme in the School section of this report.

**YOUNG PROGRAMME**

A whole day was dedicated to ESTRO’s young audience, which included a teaching lecture, symposia and networking activities.
5,860 PARTICIPANTS

- 4,333 participants
- 1,527 company delegates

85 COUNTRIES REPRESENTED

- 77% European
- 23% non-European
PARTICIPATION

PARTICIPANTS PER SPECIALTY

- 39.02% radiation oncologists
- 30.52% medical physicists
- 11.61% RTTs, RT nurses
- 5.62% clinical oncologists
- 2.61% other non-medical specialities
- 1.85% radiobiologists
- 1.39% other medical specialities
- 1.29% dosimetrists
- 0.93% computer scientists
- 0.50% RO industry - corporate

GEOGRAPHIC OVERVIEW

- Europe: 77.18%
- Asia: 8.37%
- America: 6.60%
- Middle East: 3.54%
- Australia and West Pacific: 3.31%
- South America: 0.71%
- Africa: 0.29%
PARTICIPANTS PER COUNTRY - TOP 10

1. The Netherlands: 373
   - 3,727 participants and visitors
   - 1,303 company delegates

2. Germany: 272
   - 3,496 participants and visitors
   - 1,457 company delegates

3. UK: 269
   - 4,065 participants and visitors
   - 1,219 company delegates

4. Switzerland: 262
   - 4,333 participants and visitors
   - 1,527 company delegates

5. Italy: 221
   - 1,303 participants and visitors
   - 1,527 company delegates

6. Spain: 148
7. Austria: 146
8. France: 146
9. Denmark: 140
10. Belgium: 139

EVOLUTION
NUMBER OF PARTICIPANTS AT THE ESTRO ANNUAL CONFERENCE

ESTRO 33: 5,030
- 3,727 participants and visitors
- 1,303 company delegates

3rd ESTRO Forum: 4,933
- 3,496 participants and visitors
- 1,457 company delegates

ESTRO 35: 5,284
- 4,065 participants and visitors
- 1,219 company delegates

ESTRO 36: 5,860
- 4,333 participants and visitors
- 1,527 company delegates
SCIENTIFIC PROGRAMME

ABSTRACTS - DISCIPLINARY BREAKDOWN

1,955 SUBMITTED ABSTRACTS

- Clinical: 783
- Physics: 783
- RTT: 150
- Brachytherapy: 149
- Radiobiology: 90

EVOLUTION

ABSTRACTS SUBMITTED TO THE ESTRO ANNUAL CONFERENCE

- ESTRO 33: 1,737
- 3rd ESTRO Forum: 1,637
- ESTRO 35: 2,200
- ESTRO 36: 1,955
77% of attendees surveyed felt they had learned about the latest improvements in radiation oncology.

4 percentage points compared to ESTRO 35.

72% of attendees surveyed felt they had learned about innovative high-precision technologies for imaging cancer patients.

8 percentage points compared to ESTRO 35.

55% of attendees surveyed felt they were introduced to new areas of research.

6 percentage points compared to ESTRO 35.
AWARDS

- 7 AWARD LECTURES
- 3 HONORARY MEMBER AWARDS
- 5 POSTER AWARDS
- 5 LIFETIME ACHIEVEMENT AWARDS
- 1 UNIVERSITY AWARD
- 4 COMPANY AWARDS

9 PARTICIPANTS benefited from a free registration financed by the ESTRO Ambassador Solidarity Fund

5 PEOPLE benefited from a company travel grant (sponsored by Elekta Brachytherapy) to attend ESTRO 36

EDUCATION

- 612 PARTICIPANTS attended the 7 pre-conference courses
- 254 PARTICIPANTS attended the 8 contouring workshops
From top left to bottom:
FALCON contouring workshop, lifetime achievement awardees and ESTRO Presidents, ESTRO booth in the exhibition area, opening ceremony.
EXHIBITION AND INDUSTRY

123 EXHIBITORS

13 COMMERCIAL SATELLITE SYMPOSIA were hosted

4,644 M² SOLD

EVOLUTION

NUMBER OF EXHIBITING COMPANIES AT THE ESTRO ANNUAL CONFERENCE

ESTRO 33: 105

3rd ESTRO Forum: 89

ESTRO 35: 103

ESTRO 36: 123

NUMBER OF M² SOLD IN THE EXHIBITION AT THE ESTRO ANNUAL CONFERENCE

ESTRO 33: 3,646

3rd ESTRO Forum: 3,815

ESTRO 35: 3,916

ESTRO 36: 4,644
2. Topical / organ-based conferences

2.1 ESTRO and joint multidisciplinary events

6th International Conference on innovative approaches in Head and Neck Oncology (ICHNO)
16-18 March 2017 | Barcelona, Spain
Jointly organised by ESTRO, EHNS and ESMO

This jointly organised biennial conference brings together scientists, industry and medical professionals to exchange knowledge on the most cutting-edge science and innovation in the field of head and neck oncology. The scientific programme consisted of:

743 PARTICIPANTS
134 SUBMITTED ABSTRACTS
41 INVITED SPEAKERS, DISCUSSANTS, PANELLISTS
5 KEYNOTE LECTURES
10 EXHIBITORS
5 SYMPOSIA
1 INTERACTIVE TUMOUR BOARD SESSION
1 DEBATE
1 SESSION PROVIDING UPDATES ON RANDOMISED TRIALS
GEOGRAPHIC BREAKDOWN OF THE PARTICIPANTS

743 PARTICIPANTS

- 43.75% radiation oncologists
- 23.28% other medical specialities
- 20.32% clinical oncologists
- 6.05% other non-medical specialities
- 2.55% RO industry - corporate
- 2.42% medical physicists
- 1.08% RTT (therapists), RT nurses
- 0.55% radiobiologists

PARTICIPANTS PER COUNTRY - TOP 10

1. Spain: 94
2. The Netherlands: 68
3. UK: 59
4. France: 58
5. Belgium: 56
6. Germany: 42
7. Portugal: 33
8. USA: 32
9. Denmark: 30
10. Italy: 29

EVOLUTION

NUMBER OF PARTICIPANTS AT ICHNO

- 3rd ICHNO: 599
- 4th ICHNO: 538
- 5th ICHNO: 636
- 6th ICHNO: 744
From top left to bottom: poster area; ICHNO chairs; and a speaker presenting their research.
EMUC’s mission is to improve the care of patients with urological malignancies by fostering education and knowledge exchange in urological oncology through regular international multidisciplinary meetings where insights, best practices and prospects are discussed and examined in a comprehensive and critical manner by opinion leaders. ESTRO is one of the members of the organising steering committee for these meetings.

As part of the meeting, ESTRO held a contouring workshop on ‘Target volume contouring in bladder cancer’ that had 19 participants.
**GEOGRAPHIC BREAKDOWN OF THE PARTICIPANTS**

<table>
<thead>
<tr>
<th>Region</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Europe</td>
<td>60%</td>
</tr>
<tr>
<td>Asia</td>
<td>31.2%</td>
</tr>
<tr>
<td>North America</td>
<td>5.5%</td>
</tr>
<tr>
<td>Africa</td>
<td>2.1%</td>
</tr>
<tr>
<td>South America</td>
<td>0.8%</td>
</tr>
<tr>
<td>Oceania / Australia</td>
<td>0.4%</td>
</tr>
</tbody>
</table>

**PARTICIPANTS PER COUNTRY - TOP 10**

1. **The Netherlands**: 167
2. **Belgium**: 80
3. **Spain**: 66
4. **UK**: 59
5. **Greece**: 42
6. **Germany**: 40
7. **Portugal**: 34
8. **Sweden**: 33
9. **Italy**: 28
10. **South Korea**: 28
2.2 ESTRO workshops

2017 Dosimetry Audit Workshop
11 January 2017 | Brussels, Belgium

The dosimetry audit workshop had 45 participants from all over Europe, although the majority were from the UK, Spain, The Netherlands and Denmark. Most participants came from national societies, clinical trial quality assurance (QA) groups and other authorities involved in dosimetry audits or who had published suitable work. The workshop was structured to provide an informal arena for scientific interaction and networking between researchers working in the same field. Participants were able to present the audit situation in their own country as well as their own work.

1st ESTRO Physics Workshop
Science in development
17-18 November 2017 | Glasgow, UK

The first ESTRO physics workshop aimed to strengthen scientific and professional networking among ESTRO members with interests in a common area, and to promote ‘out-of-the-box’ thinking. This was facilitated by the small format of the meeting.

Five tracks ran in parallel:
- Medical physics research, GATE Monte Carlo simulations and treatment planning development for therapy with scanned particle beams
- Dosimetry audit in radiation oncology – where to next?
- In vivo dosimetry methods for external beam radiotherapy and brachytherapy
- Micro and nano-dosimetry for radiotherapy
- Automate or perish.

The meeting aimed to outline the latest research, to promote collaboration between different groups and to enable ESTRO members working in the same field to share experiences.
92% of the participants reported that the meeting had expanded their network and that it was very relevant to their work/research and clinical practice.
BREAKDOWN OF PARTICIPANTS PER WORKSHOP

- Automate or perish: 48
- Dosimetry audit: 48
- Medical physics research, GATE: 48
- In vivo dosimetry methods: 47
- Micro and nanodosimetry: 22
- + 1 Exhibitor

214 PARTICIPANTS

BREAKDOWN OF PARTICIPANTS’ AGE

- <30 years: 35
- 30-34 years: 46
- 35-39 years: 29
- 40-44 years: 30
- 44-49 years: 31
- ≥50 years: 38
- Unknown: 5

PARTICIPANTS PER COUNTRY - TOP 10

1. UK: 50
2. The Netherlands: 29
3. Spain: 15
4. Austria: 13
5. Germany: 12
6. Sweden: 11
7. France: 8
8. Switzerland: 8
9. Belgium: 7
10. Denmark: 7
The aim of the workshop was to support the brachytherapy community in their ongoing work to identify common issues in their field and to exchange experiences.

The workshop covered the following topics:
- Head and neck, and eye brachytherapy
- Quality and costs in brachytherapy
- Breast and skin brachytherapy - recent perspectives
- Organ volumes, dose and toxicity for brachytherapy in pelvic malignancies.

Each working group had the opportunity to present its ongoing projects. The workshop also enabled GEC-ESTRO members and other attendees interested in brachytherapy to network.

PARTICIPANTS PER COUNTRY - TOP 10

1. Italy: 27
2. The Netherlands: 25
3. UK: 20
4. Poland: 15
5. Germany: 11
6. Spain: 11
7. Denmark: 10
8. Portugal: 10
9. Hungary: 9
10. Russia: 9

*Groupe Européen de Curiethérapie
NUMBER OF PARTICIPANTS TO THE GEC-ESTRO WORKSHOP

1st GEC-ESTRO workshop: 130
2nd GEC-ESTRO workshop: 206
3rd GEC-ESTRO workshop: 164
4th GEC-ESTRO workshop: 122
5th GEC-ESTRO workshop: 219
2.3 Events in scientific collaboration with ESTRO

**ECCO2017 European Cancer Congress**

*From evidence to practice in multidisciplinary cancer care*

27-30 January 2017 | Amsterdam, The Netherlands

The ECCO2017 European Cancer Congress attracted a diverse multidisciplinary audience of over 2,530 participants, including oncologists of every specialty, scientists, nurses, primary care professionals, as well as patient advocates, government officials, policymakers and representatives from ECCO member societies. They presented and discussed exciting innovations and their implementation into clinical practice, how oncopolicy can strengthen multidisciplinary practice to ensure optimal patient outcomes, as well as the challenges in cross-border cancer care.
The 7th European Lung Cancer Conference (ELCC) attracted 1,964 participants, two thirds of whom were from Europe. ELCC is a collaborative effort of the most important multidisciplinary societies representing thoracic oncology specialists, all working towards a shared goal: to advance science, disseminate and improve the practice of lung cancer specialists worldwide.
15th international Wolfsberg meeting on molecular radiation biology / oncology
20-22 June 2017 | Ermatingen, Switzerland

The 15th international Wolfsberg meeting provided a platform to discuss the latest aspects of DNA repair and signalling; the influence of micro-environmental parameters on radiation response of tumour and normal tissue; and biomarkers and interventional strategies in radiation oncology at the level of basic mechanisms and clinical perspectives.

The meeting brought together 150 participants, both experienced and young, including basic and clinical scientists from the disciplines of molecular and cell biology, tumour and normal tissue biology, and radiobiology and radiation oncology. As the number of participants for each meeting is restricted, participation is based on the quality of the submitted abstract, which is judged by a large scientific committee.

International Conference on Advances in Radiation Oncology (ICARO 2)
20–23 June 2017 | Vienna, Austria

The conference gave healthcare professionals an opportunity to review the current developments in clinical applications in the fields of radiation oncology, radiation biology and medical physics, with a view to addressing the challenge of cancer management. The conference aimed at defining the current role and future potential of technological, medical physics and molecular/biological innovations for their incorporation into routine clinical practice in radiation oncology.
2.4 Endorsed meetings

In addition to the meetings listed above, in which ESTRO joined or participated in the scientific organisation, the Society also helps to promote meetings organised by other societies, institutes or partners in the oncology community. In 2017, ESTRO supported 36 such meetings. Once their application is approved by the ESTRO Board, all of these meetings benefit from a relevant promotional package, including visibility on the ESTRO website and in the newsletter.

<table>
<thead>
<tr>
<th>Date</th>
<th>Location</th>
<th>Event Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>26-28 JANUARY 2017</td>
<td>PRAGUE, CZECH REPUBLIC</td>
<td>ESMPE imaging in radiotherapy</td>
</tr>
<tr>
<td>1-3 MARCH 2017</td>
<td>TEL AVIV, ISRAEL</td>
<td>Innovation in radio-oncology course</td>
</tr>
<tr>
<td>14-15 MARCH 2017</td>
<td>LONDON, UK</td>
<td>Gen immuno-oncology congress</td>
</tr>
<tr>
<td>19-21 MARCH 2017</td>
<td>MANCHESTER, UK</td>
<td>Sharing the vision for world-class radiotherapy symposium</td>
</tr>
<tr>
<td>19-21 MARCH 2017</td>
<td>ASSISI, ITALY</td>
<td>Think-tank meeting on research challenges in rectal cancer</td>
</tr>
<tr>
<td>6-7 APRIL 2017</td>
<td>AMSTERDAM, THE NETHERLANDS</td>
<td>13th head and neck cancer symposium</td>
</tr>
<tr>
<td>7-8 APRIL 2017</td>
<td>MELBOURNE, AUSTRALIA</td>
<td>Radiotherapy in modern lymphoma management: ILROG 2017</td>
</tr>
<tr>
<td>20 MAY 2017</td>
<td>DUBLIN, IRELAND</td>
<td>5th international stereotactic radiosurgery and stereotactic body radiotherapy symposium</td>
</tr>
<tr>
<td>28 MAY - 1 JUNE 2017</td>
<td>MONTREUX, SWITZERLAND</td>
<td>ISRS 2017 conference</td>
</tr>
<tr>
<td>12-16 JUNE 2017</td>
<td>BUCHAREST, ROMANIA</td>
<td>Standards and controversies in today's oncology and immune-oncology</td>
</tr>
<tr>
<td>14-17 JUNE 2017</td>
<td>LUGANO, SWITZERLAND</td>
<td>14th international conference on malignant lymphoma</td>
</tr>
<tr>
<td>20-23 JUNE 2017</td>
<td>SYDNEY, AUSTRALIA</td>
<td>5th MR in RT symposium</td>
</tr>
<tr>
<td>1-3 AUGUST 2017</td>
<td>TEHRAN, IRAN</td>
<td>1st international conference on head and neck cancer</td>
</tr>
<tr>
<td>22 AUGUST 2018</td>
<td>COPENHAGEN, DENMARK</td>
<td>IMRT &amp; VMAT planning in practice at ECMP2018</td>
</tr>
<tr>
<td>10-13 SEPTEMBER 2017</td>
<td>OPAL COAST, FRANCE</td>
<td>SFPM 2017 seminar</td>
</tr>
<tr>
<td>13-16 SEPTEMBER 2017</td>
<td>TORONTO, CANADA</td>
<td>CARO annual scientific meeting</td>
</tr>
<tr>
<td>18-29 SEPTEMBER 2017</td>
<td>TRIESTE, ITALY</td>
<td>ICTP-IAEA workshop on Monte Carlo radiation</td>
</tr>
<tr>
<td>20-22 SEPTEMBER 2017</td>
<td>ESSEN, GERMANY</td>
<td>Workshop on the Monte Carlo radiotherapy system PRIMO</td>
</tr>
<tr>
<td>20-23 SEPTEMBER 2017</td>
<td>LE BONO, FRANCE</td>
<td>Prediction and modelling of response to molecular and external beam radiotherapies workshop</td>
</tr>
<tr>
<td>Date/Location</td>
<td>Event Description</td>
<td></td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>-----------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>21-23 SEPTEMBER 2017, Padua, Italy</td>
<td>13th meet the professor advanced international breast cancer course</td>
<td></td>
</tr>
<tr>
<td>2-4 OCTOBER 2017, Berlin, Germany</td>
<td>ICIS annual meeting</td>
<td></td>
</tr>
<tr>
<td>5 OCTOBER 2017, Barcelona, Spain</td>
<td>Implementation of new techniques and technologies: the role of the RTTs course</td>
<td></td>
</tr>
<tr>
<td>5-6 OCTOBER 2017, Edinburgh, UK</td>
<td>BLADDR 2017 global congress on bladder cancer</td>
<td></td>
</tr>
<tr>
<td>5-6 OCTOBER 2017, Milan, Italy</td>
<td>Breast cancer biennial conference</td>
<td></td>
</tr>
<tr>
<td>5-6 OCTOBER 2017, Buenos Aires, Brazil</td>
<td>7th Inter-American oncology conference</td>
<td></td>
</tr>
<tr>
<td>9-11 OCTOBER 2017, Rome, Italy</td>
<td>27th residential course on multidisciplinary oncology and metastatic patients in the era of high-tech radiotherapy</td>
<td></td>
</tr>
<tr>
<td>12-13 OCTOBER 2017, Rome, Italy</td>
<td>Fifth annual UPMC international symposium on SRS/SBRT</td>
<td></td>
</tr>
<tr>
<td>15-18 OCTOBER 2017, Naples, Italy</td>
<td>International conference on Monte Carlo techniques for medical applications MCMA</td>
<td></td>
</tr>
<tr>
<td>19-21 OCTOBER 2017, Cluj-Napoca, Romania</td>
<td>27th RSRMO Congress</td>
<td></td>
</tr>
<tr>
<td>2-4 NOVEMBER 2017, Lisbon, Portugal</td>
<td>ABC4</td>
<td></td>
</tr>
<tr>
<td>9-11 NOVEMBER 2017, New York, USA</td>
<td>Colorectal centennial symposium</td>
<td></td>
</tr>
<tr>
<td>11-13 NOVEMBER 2017, Rimini, Italy</td>
<td>AIRO national congress</td>
<td></td>
</tr>
<tr>
<td>12-14 NOVEMBER 2017, London, UK</td>
<td>International oncology leadership conference</td>
<td></td>
</tr>
<tr>
<td>20-21 NOVEMBER 2017, Leiden, The Netherlands</td>
<td>5th world rectal conference</td>
<td></td>
</tr>
<tr>
<td>23 NOVEMBER 2017, Poznan, Poland</td>
<td>Young scientists forum</td>
<td></td>
</tr>
<tr>
<td>24 NOVEMBER 2017, Tubingen, Germany</td>
<td>Functional imaging and tumour hypoxia for radiation oncology</td>
<td></td>
</tr>
</tbody>
</table>

### 2.5 Meetings by invitation

**Conference on Experimental Research in Radiation Oncology (CERRO)**
14-21 January 2017 | Les Menuires, Trois Vallées, France

The 32nd CERRO conference, known popularly as the ‘ski meeting’, was held as per tradition in Les Menuires, Trois Vallées, France, in January. Participation is by invitation, and in this meeting there were 58 delegates from different disciplines in radiation oncology. Presentations on work in progress are the focus of the event, in order to stimulate discussions on innovative research. The meeting is also a platform for promoting collaboration and networking between members and for integrating young members into the Society.
1. ESTRO’s family of journals

This section of the Annual Report is dedicated to ESTRO’s family of four journals: Radiotherapy & Oncology, the Society’s flagship publication, and Clinical & Translational Radiation Oncology (ctRO), Physics & Imaging in Radiation Oncology (phiRO), and Technical Innovations & Patient Support in Radiation Oncology (tipsRO), which were all launched more recently to provide specialised spaces for the publication of ESTRO members’ work.
1.1 Radiotherapy & Oncology

Radiotherapy & Oncology, known as the Green Journal, is the flagship publication in ESTRO’s family of journals. Led by editor-in-chief, Michael Baumann (Heidelberg, Germany), it covers all aspects of radiation oncology, publishing themed issues, editorials and correspondence, as well as original research and review articles.

It was a year of change for Radiotherapy & Oncology in 2017. Six new editors were welcomed to the journal: Eric Deutsch, Mechthild Krause, Birgitte Offersen, Vincenzo Valentini, Uulke van der Heide and Steffen Löck. In addition, Carol Bacchus joined the team as manager of the editorial office in October.

MANUSCRIPT SUBMISSIONS

1,377 MANUSCRIPTS SUBMITTED

- 358 papers published: 26%
- Rejection rate: 74%

BREAKDOWN OF SUBMISSION TYPES

- Editorial: 7
- Original research: 1,224
- Review: 54
- Short communication: 53
- Letters to the editor: 39
Radiotherapy & Oncology has an international base of authors. In 2017, 358 manuscripts were accepted for publication from all major regions of the world.

The USA was the country that contributed the largest number of papers in 2017, with 66 publications, followed by The Netherlands (50), Germany (28), the UK (27) and then Canada (26).
ARTICLE TRANSFER SERVICE TO CTRO, PHIRO AND TIPSRO

Authors of manuscripts submitted to Radiotherapy & Oncology that are not accepted for publication may be offered the opportunity to have their manuscript transferred to ctRO, phiRO or tipsRO. The decision to transfer from the Green Journal to one of ESTRO’s new journals is that of the author.

IMPACT FACTOR

The current ‘impact factor’ for Radiotherapy & Oncology, which measures citations made in 2016 to articles published in 2015 and 2016, is 4.328.

EVOLUTION

IMPACT FACTOR TREND (2010-2016)

2017 IMPACT FACTOR NOT KNOWN YET.
Online usage of Radiotherapy & Oncology was stable in 2017, with more than 710,000 downloads.

### Online Usage: 2010 - 2016

<table>
<thead>
<tr>
<th>Year</th>
<th>Number of articles downloaded</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>515,055</td>
</tr>
<tr>
<td>2011</td>
<td>558,080</td>
</tr>
<tr>
<td>2012</td>
<td>643,522</td>
</tr>
<tr>
<td>2013</td>
<td>709,020</td>
</tr>
<tr>
<td>2014</td>
<td>600,893</td>
</tr>
<tr>
<td>2015</td>
<td>773,488</td>
</tr>
<tr>
<td>2016</td>
<td>803,997</td>
</tr>
<tr>
<td>2017</td>
<td>712,979</td>
</tr>
</tbody>
</table>

### Geographical Distribution of Online Usage

- Western Europe: 34%
- North America: 28%
- Asia: 27%
- Australasia: 5%
- Eastern Europe: 2%
- South America: 2%
- Middle East: 1%
- Africa: 1%
MOST POPULAR ARTICLES

The three most downloaded articles from *Radiotherapy & Oncology* in 2017 were:

VOLUME 122 / ISSUE 3

1. *A cardiac contouring atlas for radiotherapy*

VOLUME 122 / ISSUE 3

2. *Challenges and opportunities in primary CNS lymphoma: A systematic review*

VOLUME 123 / ISSUE 3

3. *Survival prediction of non-small cell lung cancer patients using radiomics analyses of cone-beam CT images*

MORE INFORMATION

To learn more about *Radiotherapy & Oncology* or to submit a manuscript, visit: www.thegreenjournal.com
1.2 Open access journals

ESTRO will promote and publish journal(s) and, where appropriate, additional supplementary information of the highest scientific quality and through this approach set the existing and future standards for the specialty.
Clinical & Translational Radiation Oncology

Clinical & Translational Radiation Oncology (ctRO) is edited by Pierre Blanchard (Villejuif, France) and Daniel Zips (Tübingen, Germany). The editors-in-chief welcome research on all aspects of clinical and translational radiation oncology, particularly new developments in experimental radiobiology, clinical interventions and treatments. This includes imaging and biomarker studies with a clinical endpoint, as well as research results from data sciences, epidemiology and oncopolicy.

ctRO is an open access journal. Upon acceptance of a paper, authors are asked to meet the cost of publication through an article publication fee. All members of ESTRO are eligible for a discounted fee and the fees vary depending on whether the manuscript is a full-length original research article, a short-format case report, technical note or short communication. All correspondence commenting on previously published work is published free of charge.

BREAKDOWN OF SUBMISSION TYPES

76 MANUSCRIPTS SUBMITTED

- Editorial: 1
- Original research: 56
- Review: 6
- Short communication: 7
- Case reports: 6

GEOGRAPHICAL DISTRIBUTION OF PUBLISHED PAPERS IN 2017

Authors from all over the world published their work in ctRO in 2017. Germany contributed the largest number of papers in 2017 (12 papers), followed by the USA (10), Denmark (5), the UK (5), and The Netherlands (5).

- Europe: 39
- USA / Canada: 13
- Asia: 4
- Australasia: 3
ctRO achieved a high level of online usage in 2017, with more than 27,000 downloads.

GEOGRAPHICAL DISTRIBUTION OF ONLINE USAGE

- Western Europe: 39%
- Asia: 28%
- North America: 21%
- Australasia: 4%
- Eastern Europe: 3%
- Middle East: 3%
- South America: 1%
- Africa: 1%

MOST POPULAR ARTICLES

The three most downloaded articles from ctRO in 2017 were:

1. **Beyond checkpoint inhibition – Immunotherapeutical strategies in combination with radiation**
   Eckert F, Gaipl US, Niedermann G, Hettich M, Schilbach K, Huber SM, Zips D

2. **Infrastructure and distributed learning methodology for privacy-preserving multi-centric rapid learning healthcare: euroCAT**

3. **Prospective analysis of in vivo landmark point-based MRI geometric distortion in head and neck cancer patients scanned in immobilised radiation treatment position: results of a prospective quality assurance protocol**

MORE INFORMATION

To learn more about ctRO or to submit a manuscript, visit www.ctro.science
Physics & Imaging in Radiation Oncology

Physics & Imaging in Radiation Oncology (phiRO) is edited by Ludvig Muren (Aarhus, Denmark) and focuses on medical physics and imaging in radiation oncology. The journal publishes original research articles, reviews, technical notes, short communications and correspondence. In addition, phiRO has published two themed article collections under the guidance of Ludvig Muren and guest editors – ‘Dosimetry auditing’ (guest editors: Catharine Clark and Nuria Jornet) and ‘CT developments for treatment planning dose calculations in radiotherapy’ (guest editors: Wouter van Elmpt and Guillaume Landry).

phiRO is an open access journal. Upon acceptance of a paper, authors are asked to meet the cost of publication through an article publication fee. All members of ESTRO are eligible for a discounted fee and the fees vary depending on whether the manuscript is a full-length original research article, a short-format case report, technical note or short communication. All correspondence commenting on previously published work is published free of charge.

BREAKDOWN OF SUBMISSION TYPES

- Original research: 57
- Review: 2
- Short communication: 12
- Correspondence: 1

72 MANUSCRIPTS SUBMITTED
Authors from all over the world published their work in *phiRO* in 2017. The Netherlands contributed the largest number of papers in 2017 (8 papers), followed by the USA and Denmark (4 per country), the UK (3), and Japan, Sweden and Germany (2 per country).

*phiRO* achieved a good level of online usage in 2017, with more than 12,000 downloads.

**GEOGRAPHICAL DISTRIBUTION OF PUBLISHED PAPERS IN 2017**

- Europe: 23
- USA / Canada: 4
- Asia: 2
- Australasia: 1

**ONLINE USAGE**

12,762 DOWNLOADS

**GEOGRAPHICAL DISTRIBUTION OF ONLINE USAGE**

- Western Europe: 42%
- Asia: 25%
- North America: 20%
- Australasia: 6%
- Eastern Europe: 3%
- Middle East: 2%
- South America: 1%
- Africa: 1%
MOST POPULAR ARTICLES

The three most downloaded articles from phiRO in 2017 were:

1. **Accuracy of dose calculation based on artefact corrected cone beam CT images of lung cancer patients**
   Thing RS, Bernchou U, Hansen O, Brink C

2. **National audit of a system for rectal contact brachytherapy**
   Humbert-Vidan L, Sander T, Eaton DJ, Clark CH

3. **Clinical evaluation of a novel CT image reconstruction algorithm for direct dose calculations**
   van der Heyden B, Öllers M, Ritter A, Verhaegen F, van Elmpt W

MORE INFORMATION

To learn more about phiRO or to submit a manuscript, visit www.phiro.science
Technical Innovations & Patient Support in Radiation Oncology

Technical Innovations & Patient Support in Radiation Oncology (tipsRO) is edited by Sara Faithfull (Guildford, UK) and Michelle Leech (Dublin, Ireland). The journal offers radiation therapists, nurses and supportive care specialists a forum for the publication of original research, case reports, practice development and health evaluation articles, reviews, short communications, technical notes and correspondence on topics including treatment planning and workflows, treatment delivery and verification, supportive care, psycho-oncology, education and training.

tipsRO is an open access journal. As with ctRO and phiRO, authors are asked to meet the cost of publication through an article publication fee. All members of ESTRO are eligible for a discounted fee and the fees vary depending on whether the manuscript is a full-length original research article, a short-format case report, technical note or short communication. All correspondence commenting on previously published work is published free of charge.

BREAKDOWN OF SUBMISSION TYPES

- Original research: 14
- Short communication: 3
- Case reports: 4
- Correspondence: 2

23 MANUSCRIPTS SUBMITTED
ONLINE USAGE

tipsRO achieved a good level of online usage in 2017, with more than 17,000 downloads.

GEOGRAPHICAL DISTRIBUTION OF ONLINE USAGE

- Western Europe: 40%
- Asia: 30%
- North America: 13%
- Australasia: 6%
- Eastern Europe: 4%
- Middle East: 2%
- South America: 3%
- Africa: 2%

GEOGRAPHICAL DISTRIBUTION OF PUBLISHED PAPERS IN 2017

The majority of authors who published their work in tipsRO in 2017 were from Europe.
The UK contributed the largest number of papers in 2017 (4), followed by Sweden (2) and Italy, Spain, Finland, Lebanon, The Netherlands and Japan (1 per country).
MOST POPULAR ARTICLES

The three most downloaded articles from tipsRO in 2017 were:

1. **ESTRO – ACROP guidelines for positioning, immobilisation and position verification of head and neck cancer patients for radiation therapists**
   Leech M, Coffey M, Mast M, Moura F, Osztavics A, Pasini D, Vandering A

2. **Treatment of symptomatic splenomegaly with low doses of radiotherapy: Retrospective analysis and review of the literature**
   de la Pinta C, Lizarbe EF, Luis AM, Rullán JAD, García SS

3. **Patient-reported symptoms and performance status before palliative radiotherapy in geriatric cancer patients (octogenarians)**
   Nieder C, Kampe TA

MORE INFORMATION

To learn more about tipsRO or to submit a manuscript, visit www.tipsro.science
2. The ESTRO newsletter

The ESTRO newsletter provides a more informal space for members to read about the latest developments in the radio-oncology field and its community.

In each issue expert editors, selected from the membership, curate contents for themed disciplinary ‘Corners’ or report on specific topics. The newsletter typically includes information on the latest advances in research and practice, interviews with key opinion leaders, conference findings, a selection of research papers and paper reviews. It is published every two months and welcomes contributions from ESTRO members.
THE NEWSLETTER IS ACCESSIBLE TO EVERYONE VIA THE FOLLOWING MEANS:

ON TABLET VIA THE
ESTRO NEWS APP
from the App Store for iPads
or from the Google Playstore
for Android tablets

ON SMARTPHONES
VIA THE ESTRO NEWS APP
Android only

ON WWW.ESTRO.ORG/ABOUT:
Online and offline
(by downloading the PDF
format)

TOP FIVE MOST READ CORNERS IN 2017
From the ESTRO News app and online version at www.estro.org

1. READ IT BEFORE YOUR PATIENTS
2. ESTRO CONFERENCES
3. ESTRO SCHOOL
4. PHYSICS
5. BRACHYTHERAPY
3. DOVE: ESTRO’s e-library

*ESTRO will develop and enhance its web-based portfolio of resources for the benefit of all members, taking full account of the future strategic potential of new developments in information and communication technology.*

- ESTRO VISION 2020, 1.5 (F) –

DOVE (Dynamic Oncology Virtual ESTRO) is an e-library service provided by ESTRO offering an unrivalled educational and scientific resource in radiation oncology.

Over the past years, ESTRO has gathered a wealth of peer-reviewed information in its official journal *Radiotherapy & Oncology*, in abstracts, posters and webcasts from conferences, guidelines, contouring exercises and other educational publications. Slides and presentations used during ESTRO teaching courses have been added to DOVE using a ‘flip book’ format.

DOVE is accessible online to all oncology professionals from the homepage on www.estro.org and through a single log-on.
The scientific engagement policy supports, facilitates, contributes to and/or drives research projects in line with the Society’s vision and relevance to its members. The scope of ESTRO involvement varies with the research topic, the type of research activity and the level of support requested.

On the next pages are research activities in which ESTRO was involved in 2017.
EPTN
European Particle Therapy Network

EPTN became a task force of ESTRO in February 2017. Its aim is to promote clinical and research collaboration between the rapidly increasing numbers of European particle therapy (PT) centres and to ensure that PT becomes integrated in the overall radiation oncology community.

The network held its annual meeting on 5 April 2017 at the ESTRO office in Brussels. The meeting brought together 32 delegates from 15 centres, including EORTC and CERN. Work parties (WPs) gave an update on their activities.

ACHIEVEMENTS OF WORK PARTIES (WPS) IN 2017

WP1
Clinical trials
The WP has been renamed and is now a combination of the previous WP1: Scoring of normal tissue reactions and tumour response particle / photon radiotherapy, and WP3: Towards joint clinical trials.

The WP set out two initial tasks to work on:
- identify all possible methodological problems related to clinical studies on particle therapy. Experts in the field of particle therapy met to discuss parameters to include in a checklist for minimal requirements and quality points to be used to review future studies and trial protocols. An expert committee will also be created for consultation on the design of future clinical studies on PT.
- establish a uniform prospective data registration programme at a European level for the most common tumour types treated with PT. Nine site-specific subgroups have been created.

The WP is also collaborating with the EORTC to produce high-quality clinical data in PT.

WP2
Dose assessment, quality assurance, dummy runs, technology inventory
In total, 14 centres from eight European countries confirmed their interest in contributing to this WP.

Six working groups have been created:
- Reference dosimetry: gather the experience from different centres by sharing results on this topic and propose well-defined tests for a better interpretation of the results
- Audits: create a network of centres interested in participating in reference dosimetry audits and end-to-end audits so as to propose well defined end-to-end tests with anthropomorphic phantoms
- Patient-specific verifications: look at the equipment needed for patient-specific verifications, and at the tools and criteria for the comparison between measured and planned dose
- Dosimetry tools: create a database of dosimetry equipment in use in particle therapy
- Ocular treatment: address specific topics related to this treatment

At the end of the year the WP sent PT centres a survey to get an overview of the current status of the equipment and methods used in dosimetric quality assurance.

WP3
Education
This WP was created in 2017. It is developing a questionnaire to uncover needs and resources of education in PT in Europe.

WP4
Image guidance in particle therapy (IGPT)
This WP analysed the survey launched in 2016. From discussions it was decided to put together a library of clinical practice, describing the current practice of IGPT in European centres. To this end,
four sub-groups have been established: brain / head and neck, thorax, abdomen / pelvic, and extremities.

WP5
*Treatment planning systems (TPS) in particle therapy*
Several sub-groups were formed and are looking at:
- Collective TPS specifications
- Planning standards and case solutions
- TPS commissioning and validation
- Alternatives to patient-specific verifications
- CT Hounsfield units calibration
- Robustness analysis

WP6
*Radiobiology (RBE)*
Eleven PT centres responded to the questionnaire launched to determine the current status and detailed specification of the radiobiological studies in the existing, and planned, clinical and research particle therapy centres in Europe. Results will help to guide future collaborative research.

WP7
*Health economy*
The response to the survey launched in 2016 to help produce a basic data inventory of the participating particle beam therapy centres was unsatisfactory. The WP started to rework the questionnaire and make it more focused to produce a better response.

EORTC
EORTC and EPTN have agreed to collaborate on clinical research. To this end EPTN identified an expert to take up an EORTC fellowship at EORTC and to coordinate EPTN trials with EORTC. The two will also collaborate on communication and identifying potential partners, disseminating results and sourcing funding.

PTCOG
The Particle Therapy Co-Operative Group (PTCOG) and ESTRO on behalf of the EPTN task force signed a memorandum of understanding to promote:
- science, technology and clinical particle therapy to cancer patients
- collaboration and exchange between the two societies to expand their partnerships in the field of PT.

At the moment, this includes promoting and disseminating PT at selected scientific meetings, as well as joint educational activities.

An update of activities of WPs will be given at the next annual meeting of EPTN on 28 June 2018 in London, UK.
EURAMED
European Alliance for Medical Radiation Protection Research

The European Alliance for Medical Radiation Protection Research (EURAMED: www.euramed.eu) was conceived as an idea in 2016 by five European medical societies: ESTRO, the European Association of Nuclear Medicine (EANM), the European Federation of Organisations for Medical Physics (EFOMP), the European Federation of Radiographer Societies (EFRS) and the European Society of Radiology (ESR), under the umbrella of the European Institute for Biomedical Imaging Research (www.eibir.org). It became a legal entity in 2017.

EURAMED actively contributes to the activities of CONCERT, the European joint project (EJP) on the integration of radiation protection research, working together with the other European radiation protection research platforms: European radioecology alliance (ALLIANCE); multidisciplinary European low-dose initiative (MELODI), of which ESTRO is a member; European radiation dosimetry group (EURADOS); and the European platform for nuclear and radiological emergency response and recovery (NERIS). Each platform contributes to CONCERT its own specific strategic research agenda for funding. Members of these platforms can, if successful, benefit from both research, education and training grants. In 2017, there was €7m available for such activities.
AIM
The aim of the project is the improvement of quality and therapeutic ratio in head and neck, and lung cancer treatment in randomised phase II trials.

ACHIEVEMENTS IN 2017
Work package 2
Adaptive radiotherapy to account for anatomical changes:
- Cone beam CT-based dose recalculation was shown to be more accurate than in vivo dosimetry
- A decision rule was developed to select patients for adaptive re-planning
- A database for dose accumulation was established

Work package 3
Biological adaptive treatment planning in the presence of advanced techniques:
Demonstrated that at week two of treatment it is now possible to estimate the radiosensitivity using functional imaging, thus predicting the required radiation dose.

Work package 5
Biomarkers for response prediction in head & neck tumours to cetuximab, cisplatin and radiotherapy provided important prognostic and predictive information:
- PAR and PDXK are predictive biomarkers in non-small cell lung cancer (NSCLC)
- for head and neck cancer radiomics features provided an added value to human papillomaviruses (HPV) status as prognostic and predictive biomarker treated with the combined modality radiotherapy with cisplatin or cetuximab

Work package 6
Standardisation and innovative molecular imaging for prediction and decision-making:
- A sub-regional analysis for multiparametric imaging in NSCLC showed the potential of sub-region classification as a biomarker for prognosis
- A data-driven methodology was developed to predict hypoxia levels and hypoxia spatial patterns using CT, fluorodeoxyglucose (FDG) PET, and dynamic contrast enhanced (DCE)-CT features in NSCLC
• The potential was demonstrated of CBCT radiomics to be used as prognostic imaging biomarker

**Work package 7**

*Dose-escalation by boosting radiation within primary tumour based on a pre-treatment FDG-PET-scan in NSCLC: randomised phase II trial:*

• patient accrual ended in October 2017 with 107 randomised and 150 registered patients
• completion of analysis of data will end in 2018

**Work package 8**

*Phase III head and neck clinical trial: a randomised study with cisplatin or cetuximab and standard or adaptive high dose radiotherapy for advanced head and neck cancer:*

• patient accrual started and has reached 181 and will end in 2019

For more information, visit: www.cancerartforce.eu
ESTRO has developed four guidelines that were all published in 2017. All the guidelines are published on DOVE (ESTRO’s e-library, accessible from www.estro.org homepage).
Guidelines for positioning, immobilisation and position verification of head and neck patients for radiation therapists
Developed under the guidance of Advisory Committee on Radiation Oncology Practice – ACROP
Published online on 1 February 2017 in tipsRO

Recommendations for performing bladder-sparing treatment with brachytherapy for muscle-invasive bladder carcinoma
Developed under the guidance of GEC-ESTRO-ACROP
Published in March 2017 on Radiotherapy and Oncology
www.thegreenjournal.com/article/S0167-8140(16)34463-2/fulltext

Consensus guideline on implementation and practice of SBRT RT for peripherally located early stage NSCLC
Developed under the guidance of Advisory Committee on Radiation Oncology Practice – ACROP
Published in July 2017 on Radiotherapy and Oncology
www.thegreenjournal.com/article/S0167-8140(17)30376-6/fulltext

Technology for precision small animal radiotherapy research: Optimal use and challenges
Developed under the guidance of Advisory Committee on Radiation Oncology Practice – ACROP
Published online on 18 December 2017
www.thegreenjournal.com/article/S0167-8140(17)32733-0/fulltext

ESTRO was also involved in the following two guidelines:

Quality control in cone-beam computed tomography (CBCT)
EFOMP-ESTRO-IAEA protocol
Published online 1 February 2017 on European Journal of Medical Physics
www.physicamedica.com/article/S1120-1797(17)30183-7/fulltext

Stereotactic Body Radiation Therapy for Early Stage Non-Small Cell Lung Cancer: an ASTRO Evidence-Based Guideline
ASTRO evidence-based guideline
Endorsed by ESTRO
Published online on 5 June 2017.
www.practicalradonc.org/article/S1879-8500(17)30121-2/fulltext
www.practicalradonc.org/cms/attachment/2097635109/2078316787/mmc1.pdf
The ESTRO School is an international institution whose mission is to:
• improve, professionalise and harmonise knowledge and practice in radiation oncology and associated professions in Europe and beyond
• support the implementation of the European core curricula, with education and training programmes targeting both young and senior radiation oncology professionals
• offer a wide range of live educational activities and online educational resources that allow professionals worldwide to acquire the knowledge, skills and competencies to deliver high-quality treatment and care to cancer patients.

In 2017 the School developed a wide array of educational activities, including:

- Annual live teaching courses covering the basic and continuing medical educational needs of all professionals working in the field of radiation oncology
- Pre-meeting teaching courses, workshops, multidisciplinary tumour board sessions and teaching lectures during congresses
- E-learning courses and tools
- Hands-on experience through a mobility grants programme

*ESTRO members benefit from a discount on fee registration for all the courses and e-learning activities.*
LIVE COURSES

1. Wide range of topics proposed

The portfolio of live teaching courses includes basic and more advanced courses targeted at the various radiation oncology professions.

The topics cover the main areas of radiation oncology and multidisciplinary cancer treatment:

- **13 COURSES ON**
  - Radiotherapy treatment planning and delivery: external beam and brachytherapy

- **14 COURSES ON**
  - Multimodal cancer treatment, in general, and also site-specific treatment

- **2 COURSE ON**
  - Biological aspects of radiation oncology

- **4 COURSES ON**
  - Imaging

- **3 COURSES ON**
  - Best practice

- **3 COURSES ON**
  - Research

Some courses take place only every second year.

The courses are accredited by the European Accreditation Council for Continuing Medical Education (EACCME) and by the European Federation of Organisations for Medical Physics (EFOMP), and participants receive corresponding credits as well as certificates of attendance.
Dose modelling and verification for external beam radiotherapy
2-6 April 2017
Warsaw, Poland

ESTRO/ESNM course on molecular imaging and radiation oncology
10-13 April 2017
Bordeaux, France

Research masterclass in radiotherapy physics
10-13 September 2017
Florence, Italy

IMRT and other conformal techniques in practice
8-13 April 2017
Madrid, Spain

Multidisciplinary management of breast cancer course
10-13 September 2017
Dublin, Ireland

ESTRO/ESNM course on molecular imaging and radiation oncology
10-13 April 2017
Bordeaux, France

Brachytherapy for prostate cancer
29 June - 1 July 2017
Brussels, Belgium

Dose modelling and verification for external beam radiotherapy
2-6 April 2017
Warsaw, Poland
2. 2017 programme at a glance

GEOGRAPHICAL BREAKDOWN OF LIVE COURSES

- In Europe: 29 courses
- Outside Europe: 5 courses

BREACKDOWN OF PARTICIPANTS ON LIVE COURSES

- In Europe: 2,149
- Outside Europe: 427

34 LIVE COURSES

2,576 PARTICIPANTS
EVOLUTION

GROWTH IN THE NUMBER OF PARTICIPANTS OVER THE YEARS

<table>
<thead>
<tr>
<th>Year</th>
<th>Courses / Year</th>
<th>Participants / Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005</td>
<td>14</td>
<td>1,434</td>
</tr>
<tr>
<td>2006</td>
<td>16</td>
<td>1,826</td>
</tr>
<tr>
<td>2007</td>
<td>19</td>
<td>1,976</td>
</tr>
<tr>
<td>2008</td>
<td>23</td>
<td>2,611</td>
</tr>
<tr>
<td>2009</td>
<td>28</td>
<td>2,745</td>
</tr>
<tr>
<td>2010</td>
<td>30</td>
<td>2,836</td>
</tr>
<tr>
<td>2011</td>
<td>31</td>
<td>2,843</td>
</tr>
<tr>
<td>2012</td>
<td>32</td>
<td>3,015</td>
</tr>
<tr>
<td>2013</td>
<td>33</td>
<td>2,858</td>
</tr>
<tr>
<td>2014</td>
<td>34</td>
<td>2,581</td>
</tr>
<tr>
<td>2015</td>
<td>33</td>
<td>2,490</td>
</tr>
<tr>
<td>2016</td>
<td>34</td>
<td>2,822</td>
</tr>
<tr>
<td>2017</td>
<td>34</td>
<td>2,576</td>
</tr>
</tbody>
</table>

EVOLUTION OF THE GEOGRAPHIC BREAKDOWN OF COURSE PARTICIPANTS OVER THE YEARS

Courses held:
- **In Europe**
- **Outside Europe**
BREAKDOWN OF PARTICIPANTS FOR COURSES ORGANISED IN EUROPE IN 2017

PER CONTINENT

Europe: 84%
Asia and Pacific: 12%
North America: 2%
Middle East and North Africa: 1.2%
Africa: 0.5%
South America: 0.3%

TOP 10 COUNTRIES

1. The Netherlands: 197
2. Greece: 125
3. Poland: 104
4. Spain: 101
5. UK: 98
6. Belgium: 97
7. Denmark: 92
8. Switzerland: 81
9. Norway: 80
10. Germany: 76
PER DISCIPLINE

- 1,012 radiation oncologists
- 639 medical physicists
- 238 RTTs
- 151 clinical oncologists
- 58 other medical specialities
- 20 other non-medical specialities
- 20 dosimetrists
- 20 radiobiologists
- 12 RO industry – corporate
- 5 computer scientists

BY ESTRO MEMBERSHIP

- 77% members
- 23% non-members
ESTRO offers one-day teaching courses prior to its annual congress. Seven pre-meeting courses were organised in Vienna, Austria, on 5 May at ESTRO 36:

**Pre-meeting courses**

**INTERDISCIPLINARY PRE-MEETING COURSE**
Integration of multimodality imaging in radiation oncology to improve target definition and modified dose prescription

**RADIOBIOLOGY PRE-MEETING COURSE**
Clinical application of biomarkers: how to discover, explore, and validate biomarkers for normal tissue toxicity and tumour response

**PHYSICS PRE-MEETING COURSE**
Medical physics aspects of particle therapy

**GEC-ESTRO WORKSHOP**
Innovations in brachytherapy

**RTT PRE-MEETING COURSE**
Quality and risk management in practice

**ESTRO-EORTC WORKSHOP**
Methodologies for conducting trials and other studies, including data handling and analysis
Multidisciplinary tumour board sessions

In the ESTRO multidisciplinary tumour board sessions, experts from different oncology disciplines discuss one or two cases in depth, sharing their experience, thought-processes and decision-making about the best approach to treatment with the audience.

Three multidisciplinary tumour board sessions were organised at ESTRO 36 on:
1. FALCON EduCase, the contouring platform

FALCON* EduCase is ESTRO’s web-based contouring programme, devoted to improving contouring skills of radiation oncology professionals.

Variability in anatomical contouring is an important contributor to uncertainty in radiation oncology. This is why a few years ago ESTRO developed the contouring programme FALCON* based on the EduCase software, aiming to improve contouring skills and to compare individual contours with those made by delineation experts and with the ESTRO / international guidelines.

The FALCON EduCase online contouring platform is integrated into the portfolio of educational ESTRO activities such as:

- **LIVE COURSES**
- **WORKSHOPS AT ESTRO MEETINGS**
- **ONLINE VIRTUAL WORKSHOPS**
- **DELINEATION WORKSHOPS FOR OTHER SOCIETIES**
  (IAEA, national societies or other societies active in the field of oncology)
- **SUPPORT SERVICES FOR CLINICAL TRIALS AND DEVELOPMENT OF GUIDELINES**

*Fellowship in Anatomic deLineation and CONtouring*
2. Online Falcon delineation workshops take off

ESTRO launched the FALCON delineation platform at the end of 2010, with delineation exercises incorporated into a number of live courses. Later, several online workshops were organised to provide blended learning on contouring for participants around the world. This new approach started slowly, but in 2017 these online workshops took off. Eleven workshops were organised during the year and thanks to improved promotion and word-of-mouth recommendation, they were attended by an average of 25 participants per workshop.

### EVOLUTION

**NUMBER OF PARTICIPANTS TO ONLINE DELINEATION WORKSHOPS**

<table>
<thead>
<tr>
<th>Year</th>
<th>Workshops / Year</th>
<th>Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>7</td>
<td>106</td>
</tr>
<tr>
<td>2016</td>
<td>8</td>
<td>70</td>
</tr>
<tr>
<td>2017</td>
<td>11</td>
<td>258</td>
</tr>
</tbody>
</table>

### DELINEATION EXERCISES IN ESTRO LIVE COURSES:

16 ESTRO live courses used FALCON EduCase for contouring exercises in 2017

### DELINEATION WORKSHOPS FOR THIRD PARTIES:

FALCON EduCase was also used at live workshops at events organised by third parties, including: the International Conference on Malignant Lymphoma and EMUC, IAEA, ISCO and RANZCR conferences.

### STRATEGIC MILESTONE

Alongside these activities, ESTRO and the International Atomic Energy Agency (IAEA) initiated a collaborative project examining the benefit of education in delineation. The first results of this study confirm that education in contouring improves homogeneity in delineation, showing both a short- and long-term benefit. This highlights the importance of FALCON in delivering continuous education.
3. Workshops at the ESTRO annual congress

In addition to the pre-meeting courses, ESTRO also offers hands-on delineation workshops during the annual congress.

8 contouring workshops were organised
- 2 intraprostatic relapses
- 2 liver stereotactic body radiation therapy (SBRT)
- 2 anal canal
- 2 spine SBRT

Breakdown of participants per contouring workshop

251 participants

- Prostate: 37
- Anal canal: 60
- Spine SBRT: 75
- Liver SBRT: 79
4. Next steps

In 2017, the FALCON programme saw a record number of courses and workshops use the EduCase tool. In 2018, we have 14 courses, eight workshops and 10 online workshops planned in which EduCase will be used. We also expect that several third party workshops will be held around the world.

As ESTRO School is pushing towards blended learning throughout its educational activities, FALCON will work together with Moodle to create an effortless learning experience for course participants. In addition, we will investigate further integrating FALCON with ESTRO courses through discussion with the course directors.

As FALCON can be used in research projects, additional efforts are being made to advertise the possibilities of EduCase in various clinical trials and guideline projects. Technical developments will include the development of statistical tools and other contouring tool evolutions.

5. Hands-on training

Mobility grants

Every year, ESTRO dedicates a budget of €50,000 for mobility grants (technology transfer grants or TTGs).

These grants are to enable radiation oncology professionals to visit another institute to learn about or gain experience with a technique, equipment or application that is not available in their own institute, and which would be useful for them and their department in future studies or clinical treatments.

Applications are submitted twice a year and evaluated by a panel of five members of the education council, including two clinicians, one physicist, one radiation therapist (RTT) and one biologist.

- 86 proposals
- 25 funded (29% funded)
Reduced fees

Reduced (subsidised) fees to attend live courses organised in Europe can be granted to ESTRO members working in countries where there may be less financial support available for education. Eligibility is based on specific criteria and candidates must submit an application. The registration fee is reduced to €350 for successful applicants.

In 2017, 233 members were granted reduced fees.

THE TOP EIGHT COUNTRIES FOR SUCCESSFUL APPLICANTS

1. Greece: 66
2. Hungary: 33
3. Slovenia: 28
4. Romania: 24
5. Spain: 20
6. Czech Republic: 13
7. Turkey: 11
8. Poland: 8

TYPE OF SUPPORT FOR COURSE PARTICIPANTS IN 2017

- 48% SUBSIDISED FEES:
  ESTRO members working in countries with a less competitive economic background can obtain a reduced participation fee of €350 to attend live teaching courses organised in Europe.

- 47% IAEA:
  Funding provided by the International Atomic Energy Agency for radiation oncology professionals from their Member States to participate in ESTRO courses.

- 4% EDUCATIONAL GRANT:
  Educational grants sponsored by ESTRO Corporate Members are available for ESTRO members in training wishing to participate in ESTRO Teaching Courses.

- 1% SOLIDARITY FUND:
  The ESTRO Ambassador Solidarity Fund, financed by the ESTRO Supporting Ambassador Members, enables a number of young radiation oncology professionals from European economically challenged countries to participate in ESTRO courses in Europe.
First steps towards revising the core curriculum for clinicians

The aim of the ESTRO core curriculum is to develop comparable standards for training in radiation oncology across Europe and to facilitate free movement of doctors across borders. In addition, it is intended to ensure that non-technical competences are well represented.

Recent developments in education, together with major advances in scientific understanding, in the practice of radiation oncology and the more widespread use of systemic therapies, such as immunotherapy, led the ESTRO education council to recommend a further revision of the medical curriculum.

An initial meeting to begin work on this was held in Brussels, Belgium, in October 2017, and was attended by representatives from 20 countries, the IAEA and members of the young ESTRO group. At the meeting it was agreed that the first draft of the revised curriculum will be sent for review by all national societies, as well as educationalists in Canada and Australia, in 2018.
New courses on leadership and basic clinical communication

In 2015, the CanMEDS framework replaced the domain of ‘manager’ with that of ‘leader’: as leaders, physicians engage with others to contribute to a vision of high-quality healthcare systems and take responsibility for the delivery of excellent patient care through their activities as clinicians, administrators, scholars or teachers. Following this, 20 leadership competences with global applicability were defined.

Responding to this change in emphasis, ESTRO has worked with the Canadian Association of Radiation Oncology (CARO) and the Royal Australian and New Zealand College of Radiologists (RANZCR) to develop an international programme on leadership. The first course on ‘Foundations of leadership in radiation oncology’ will take place in April 2018 and the number of applications received by the end of 2017 was already above capacity. The course is aimed at professionals interested in developing expertise in leading teams, advocacy and positively influencing the future of radiation oncology, both locally and internationally. The course combines online and live sessions and will be held on a different continent each year.

In addition to medical expertise, the CanMEDS framework advocates training in six competencies: scholarship, professionalism, collaboration, health advocacy, leadership and communication. The ESTRO School therefore decided to develop a new course on ‘basic clinical communication’ to equip physicians with knowledge of the communication skills necessary to handle frequently occurring challenges in cancer care, including uncertainty, anxiety, emotional turbulence, delivery of complex information, and breaking bad news. A trial workshop was held in January 2017 at the European Cancer Congress (ECCO) in Amsterdam, The Netherlands. The workshop was well received and it has been decided to make it a regular ESTRO course.

The CanMEDS model

The Royal College of Physicians and Surgeons of Canada (CanMEDS) have produced a framework for core curriculum design that identifies seven domains in which competencies need to be acquired.

All three curricula (for clinicians, physicists and RTTs) were revised in 2011, with a change in focus from theoretical knowledge and skills to competency-based education. Competencies are the observable abilities of healthcare professionals. A competency-based curriculum is orientated around desired outcomes, with trainees demonstrating they have achieved the required skills and perform them in day-to-day practice, rather than tracking time spent in training. The curricula were based on the CanMEDS framework and were endorsed by the Union Européenne des Médecins Spécialistes (UEMS). The upcoming core curriculum revision will rely on this model again.
‘Radiotherapy cures cancer today. Help us close the gap in access to treatment’ event at the European Parliament on 5 December 2017, Brussels, Belgium
Conclusion of work package 3: HERO cost-accounting model

The HERO project has successfully developed a model to estimate the national cost of radiotherapy, bringing this work package to a close. This is an important milestone for our community in terms of developing a solid knowledge base on the costs of radiotherapy and encouraging more economic evaluations of radiotherapy.

The HERO cost-accounting programme for radiotherapy is designed to calculate the cost of radiotherapy at the national level, using the time-driven activity-based costing methodology. The model uses national data on staffing, equipment and radiotherapy treatment, that are input by national societies (the end user) to provides results on overall cost, cost breakdown for each type of human and equipment resource, and refined cost per treatment. The model is able to specify the costs for different tumour types, techniques, fractionation schedules and other complexities.
Brachy-HERO

With strong links to the HERO project, Brachy-HERO is a working group of Groupe Européen de Curiethérapie (GEC)-ESTRO, whose task is provide a health economics analysis of brachytherapy. Brachy-HERO set up a group of experts to begin a European survey on the cost of brachytherapy. Collected data from this survey will provide the basis for future analysis.

Pre-meeting with CCORE at ESTRO 36

At ESTRO 36, ESTRO-HERO and the Collaboration for Cancer Outcomes, Research and Evaluation (CCORE) organised a workshop on health services research, with a focus on radiation oncology costs, cost effectiveness, needs and utilisation. The meeting, which was attended by 56 people, hosted a panel of international speakers and offered an overview of ongoing research in the field, enabling discussion between various research groups, and facilitating networking and collaboration.

Belgian Health Care Knowledge Centre (KCE) study

As part of the HERO project, ESTRO has collaborated with the Belgian Health Care Knowledge Centre (KCE) on a report analysing the Belgian healthcare landscape, in which radiotherapy was chosen as one of the case studies. ESTRO contributed a chapter to the report, providing a picture of radiotherapy services in Belgium, including comparative examples of how radiotherapy services are organised in other European countries, including Denmark, The Netherlands, Ireland, France and the UK, and concluding with some recommendations. The main object of the KCE report was to make recommendations on the planning of equipment resources in the future, based on international recommendations and the HERO-forecasted need for radiotherapy in 2025.

*KCE report downloadable at [bit.ly/2pf8NRx](bit.ly/2pf8NRx)*
*Section on Radiotherapy Services pages 316-379.*
National societies’ meeting

The annual national societies’ meeting at ESTRO 36 hosted 60 participants from 21 countries. The meeting provides an opportunity for national societies’ presidents and representatives to be updated on ESTRO activities, share the needs of their societies and offer input into each other’s work. HERO was one of the main topics discussed, along with research opportunities, new platforms, collaborative initiatives such as ROSEIS (Radiation Oncology Safety Education and Information System) and DIRAC (Directory of Radiotherapy Centres), and developments in ESTRO activities, particularly in relation to the ESTRO School and public affairs.

HERO workshop

The national societies are the intended end-users of the HERO costing model, and their needs and input was vital in the conceptualisation of the model. The model was presented to national society representatives at a workshop in December 2017, attended by 26 people from 18 countries. The attendees included radio-oncologists, medical physicists and radiation therapists. The workshop provided an opportunity for national societies and interested parties to familiarise themselves with the costing model and its methodology. Further training and roll-out of the model is planned for 2018.
Event at the European Parliament: ‘Radiotherapy cures cancer today. Help us close the gap in access to treatment’

5 December 2017 | Brussels, Belgium

With the objective of empowering national societies to influence decision-makers, the HERO workshop concluded with a policy symposium at the European Parliament, hosted by member of the European Parliament (MEP) Lieve Wierinck (Belgium, Alliance of Liberals and Democrats for Europe). With a health economics focus, the symposium brought together more than 65 attendees – policy-makers, experts in cancer care, patients, health advocates, industry representatives, delegates from national radiotherapy societies and citizens – to discuss access to radiation oncology care for all patients in need in Europe.

Views were shared on a wide range of topics including multidisciplinary care, education, better data gathering, putting patients at the centre of care, cancer planning, the need for investment and partnership between private and public stakeholders, as well as greater public awareness.
Patients advisory group (PAG)

The first ESTRO patient advisory group (PAG) was established in July 2017. Its first meeting looked at ambitious goal setting, together with practical short and long-term proposals. Since then the group has developed these ideas, presenting them to the ESTRO stakeholder council, and contributing to the Patients’ Day at the ESTRO 37 conference. Other activities include the creation of a brochure for patients and providing input at the stakeholder council.

The PAG comprises representatives from three partner organisations: the European Cancer Patient Coalition (ECPC), Europa Donna and Europa Uomo. The PAG’s chair also made a presentation on the patient perspective at the recent ESTRO symposium ‘Radiation oncology cures cancer today’, organised in December 2017 at the European Parliament.

Patients’ Day at ESTRO 36

The Patients’ Day at ESTRO 36 in Vienna involved a half-day of presentations and discussion. It was a fruitful exchange between patients and experts, attended by around 60 participants. Patients were invited to discuss their concerns with experts and ask for recommendations on the day’s programme, half of which was dedicated to breast cancer and the other half to prostate cancer.
Dialogue with COCIR

For ESTRO, a constructive exchange and continuous dialogue with corporate stakeholders plays a key role in the advancement of radiotherapy. ESTRO’s relationship with the European Coordination Committee of the Radiological, Electromedical and Healthcare IT Industry (COCIR) has been fostered for a number of years.

In March 2017, ESTRO attended the open session of the COCIR’s general assembly, which focused on value-based healthcare. Data on radiotherapy were presented, with a focus on the balance between innovation and cost, the impact on the patient, and the importance of generating solid evidence.

See ‘Membership’ section on page 7.
Memorandum of Understandings (MoUs)

- ESTRO and the American Association of Physicists in Medicine (AAPM) collaboration on science, including joint symposia, guidelines, education, professional awareness and student exchange programmes

- ESTRO, the European Society of Gynaecological Oncology (ESGO) and the European Society of Pathology (ESP) collaboration on cervical cancer guidelines.

World Cancer Research Day

ESTRO supported World Cancer Research Day on 24 September 2017, a global action to support research on cancer, which is promoted by a number of major oncology partners. Communication material was produced to highlight the importance of research in cancer, and our members shared photos and videos via social media, explaining and demonstrating their engagement in research.

European CanCer Organisation (ECCO)

ECCO held its board elections in 2017. An ESTRO representative has been elected.

ESTRO experts are represented on the following ECCO working groups:
- Integration of primary care and secondary care in the cancer care continuum
- Melanoma and oesophago-gastric cancer
- Breast cancer
- Prostate cancer.

Under the aegis of ECCO, and led by Professor Yolande Lievens, ESTRO President, a working group on value-based healthcare has been established, focusing on the applicability of existing value frameworks in the pharmaceutical sector towards non-systemic oncology treatment (e.g., radiation oncology and surgery). ESTRO experts are involved. An initial paper of the project’s early conclusions and recommendations will be published in 2018, and will be discussed at the ECCO 2018 European Cancer Summit in Vienna, Austria, in September 2018.
ESTRO has developed its collaboration with the European Society for Paediatric Oncology (SIOPE) under the framework of joint EU-wide action on rare cancers, for which SIOPE is managing one of the work packages focusing on paediatric oncology. ESTRO’s experts are part of the research group.

ESTRO became an associate partner of the European network for Rare adult solid Cancer (EURACAN), ensuring that the radiation oncology perspective is included in the network working groups. An ESTRO expert takes part in the EURACAN general meeting.

ESTRO was invited to participate in the first European Alliance for Personalised Medicine (EAPM) Congress, in November 2017 in Belfast, Northern Ireland, UK. ESTRO’s representative took part in the panel discussion on shaping EU policy on lung cancer screening and planning for implementation across Europe.

European Society for Paediatric Oncology (SIOPE) and rare cancers

ESTRO has developed its collaboration with the European Society for Paediatric Oncology (SIOPE) under the framework of joint EU-wide action on rare cancers, for which SIOPE is managing one of the work packages focusing on paediatric oncology. ESTRO’s experts are part of the research group.

European network for rare adult solid cancer (EURACAN) associate partner

ESTRO became an associate partner of the European network for Rare adult solid Cancer (EURACAN), ensuring that the radiation oncology perspective is included in the network working groups. An ESTRO expert takes part in the EURACAN general meeting.
European Society of Radiology (ESR) and EU Health Policy Platform (HPP) statement

ESTRO is a signatory to the joint statement of the thematic network on medical training and professional development for patient safety, led by the European Society of Radiology (ESR), part of the EU Health Policy Platform (HPP). The statement highlights the importance of medical education for all healthcare professionals and disciplines, with emphasis placed on safety and quality for the benefit of patients.

Global Impact: Radiotherapy in Oncology (GIRO)

In 2017 a group of committed experts from ESTRO, IAEA, UICC, CCORE and the Princess Margaret Cancer Centre (Canada) set up a new partnership building on the HERO and Global Task Force on Radiotherapy for Cancer Control (GTFRCC) initiatives: Global Impact: Radiotherapy in Oncology (GIRO). Using a project-based approach, GIRO aims to tackle the global challenge of access to radiotherapy to create awareness of current problems and help provide solutions, with the aim of saving one million lives by 2035. During ESTRO 36, a session was dedicated to GIRO: ‘GTFRCC: where to go from here?’.

Communities Pavilion

Oncology societies, national societies and other partners were invited to the Communities Pavilion at ESTRO 36. Each participating organisation was offered a booth to welcome visitors. The 15 participating organisations are listed in the ‘Membership’ section on p13.
The radiation oncology safety and quality committee (ROSCQ) convened several times during the year to discuss the development and launch of the revamped ‘radiation oncology safety education and information system’ (the ROSEIS platform, formerly the ROSIS reporting tool). The committee, and the platform, which were developed to facilitate the exchange on safety and quality within the radiotherapy community, continues to engage with the project and new developments. Representatives from the group have participated in a number of external meetings in 2017. They are listed below.

International Atomic Energy Agency (IAEA) meetings:

**Consultative meeting on ‘Strengthening of safety culture in radiotherapy through the use of incident learning systems’**

10-13 October 2017 | Vienna, Austria

The meeting included presentations from the AAPM, ASN and IAEA, providing insights on radiotherapy incidents and safety culture. Some of the major incidents in radiotherapy were highlighted as learning opportunities, with comparisons made to the aviation industry. The importance of patient involvement in the process was also noted, as well as local radiation safety ‘champions’, including physicians, medical physicists and radiation therapists. There was a general consensus on the need to share learning from incidents in order to benefit the wider radiotherapy community.
Consultative meeting on ‘Information technology security and integration in radiotherapy and diagnostic imaging’
23-25 October 2017 | Vienna, Austria
This meeting highlighted the need for IT security and minimising risk in relation to vendor products and digital workflow in the radiotherapy department. As a community, we should consider emerging medical software, which aims to improve safety, accuracy and reliability, as well as the security of patient portals and shared databases.

IAEA conference on ‘Radiation protection in medicine’
11-15 December 2017 | Vienna, Austria
The ROSQC chair presented on ‘Activities and priorities in line with the Bonn call for action’, emphasising ESTRO’s commitment to supporting the call. They also explained that radiation protection is a core component of the three core curricula for radiation oncologists, medical physicists and radiation therapists. Dissemination is further supported through the ESTRO national societies and close links established with the EU community related to quality and safety, as well as a patient representative sitting as a full member of the ROSQC.
Radiological protection event

4th international symposium on the system of radiological protection (ICRP) and 2nd European radiological protection research week (ERPW)  
10-12 October 2017 | Paris, France

The ROSQC chair represented ESTRO at the meeting, which was aimed at integrating European research and enhancing the robustness of European radiation and environmental protection. The wide-ranging programme was developed by five European platforms: the Multidisciplinary European LOw Dose Initiative (MELODI), the European Radioecology Alliance, the European Radiation Dosimetry Group (EURADOS), the European Alliance for Medical Radiation Protection Research (EURAMED, specialising in medical applications), the European Platform on Preparedness for Nuclear and Radiological Emergency Response and Recovery (NERIS), and the International Commission on Radiological Protection (ICRP).
In Europe, it is estimated that one in every two cancer patients should receive radiotherapy during the course of their cancer treatment. However, at present, a quarter of all European cancer patients do not receive the radiotherapy they need.

Barriers such as a lack of resources – in terms of radiotherapy equipment, staff and education – and a lack of knowledge of radiotherapy, contribute to reducing the opportunity for patients to receive the treatment that best corresponds to their disease. This contributes to the existing gap between the optimal and the current utilisation of radiotherapy in Europe.

The European Cancer Fund (ECF) tackles the barriers that prevent patients receiving the radiation treatment they need.

The ECF supports projects that are designed to:

- **RAISE AWARENESS**
  and ensure understanding of radiotherapy

- **FACILITATE RESEARCH**
  and ensure that research is disseminated and accessible

- **PROMOTE EDUCATION**
  to produce highly qualified leaders in radiation and oncology
On 7 November 2017 ECF launched the Marie Curie Legacy Campaign to commemorate the 150th anniversary of the birth of Marie Curie, the ‘mother of radiotherapy’. The project is part of the media campaign legacy project aiming to raise awareness of the benefits of radiotherapy in curing cancer.

The key elements of the project were:

- An educational animated film about Marie Curie and the legacy she left to human kind
- A website that was used to host the campaign, and which will evolve over time as future elements of the campaign are developed
Campaign accomplishments

Thanks to the campaign and the video animation, ECF aims to create a community of radiotherapy believers and ambassadors, including civil society, patients, caregivers and healthcare professionals, that can amplify ESTRO messages, raise awareness, and empower patients to take informed decisions. Ultimately the aim is to influence key decision-makers. The successful launch of the campaign produced a range of positive metrics and results.

- The video exceeded our view target by 79% and has been watched in full more than 250k times
- The website also had many visitors, who watched the video and read about Marie Curie’s life
- The campaign was tested on the Belgian traditional media market and generated substantial interest among both Dutch and French speakers focusing on the 150-year legacy and radiotherapy as an effective cancer treatment that can address under-provision.

Short term Project Planning Timeline 2017

<table>
<thead>
<tr>
<th>WP 1 &amp; WP2</th>
<th>WP 1 &amp; WP2</th>
<th>WP 1 &amp; WP2 &amp; WP3</th>
</tr>
</thead>
<tbody>
<tr>
<td>SEPTEMBER - OCTOBER</td>
<td>7 NOVEMBER 2017</td>
<td>DECEMBER - FEBRUARY</td>
</tr>
<tr>
<td>• Build consensus</td>
<td>• Launch media campaign, website, establish SoMe presence</td>
<td>• Continue raising awareness by distributing simple, unexpected, concrete, credible, messages about RT benefits using all platforms</td>
</tr>
<tr>
<td>• Identify key themes</td>
<td>• Launch MC Video Contest</td>
<td></td>
</tr>
<tr>
<td>• Establish collaboration – outsource Media Campaign execution</td>
<td>• Disseminate educational video (s)</td>
<td></td>
</tr>
<tr>
<td>• Media Campaign &amp; MC contest branding, content definition (messages &amp; stories reinforcing “RT cures cancer safely today”), testing</td>
<td>• Collect stories</td>
<td></td>
</tr>
</tbody>
</table>

Vision for 2018

The results of the Marie Curie Legacy Campaign have helped to build a strong platform for the ESTRO Cancer Foundation (ECF) to continue advocating for changes in policy decision-making, and to ensure that those in charge of making policy at both the EU and national levels are engaged and receive the information they need to take informed choices on healthcare policies. This year, the ECF will continue its work with the organisation of a policy forum in Brussels in November 2018.
The Marie Curie campaign in the traditional press and social media

While the focus of the public relations activity in this campaign was on Belgium as a test platform, a genuine interest was shown by the Belgian press at the launch of the campaign, which resulted in 25 media clippings.

RTBF:
Jean-François Daisne, BVRO/ABRO President, addresses the role of women in curing cancer in the context of the 150th anniversary of Marie Curie’s birth (in French).

RTBF:
RTBF: The “curietherapy” – the legacy of Marie Curie

GAZET VAN ANTWERPEN:
Yolande Lievens, ESTRO President, addresses the under provision of radiotherapy utilisation in curing cancer in Belgium for the Dutch-speaking public.

FACEBOOK: @JCMarcourtOfficiel
TWITTER: @jcmarcourt
Vice-President of the Wallonia-Brussels Federation and Belgian Minister of Higher Education, Research and Media.
In 2017, as part of ESTRO 36, the ESTRO Cancer Foundation organised the 3rd Super Run, with 400 runners, divided into 130 teams, running a 5km relay across Vienna’s Prater park. The Super Run is designed to raise awareness of radiotherapy, bringing together congress participants, healthcare professionals and patients to highlight the importance of physical activity during and after treatment.
The figures presented in this report were approved at the ESTRO general assembly on 8 May 2017 at ESTRO 36.

In 2016, operating revenues rose to almost €7.25 million, led by registrations at meetings and courses, exhibition and membership subscriptions.

The financial incomes represented an amount of €7,000 while the financial charges, including bank charges and credit card commissions, represented €54,000.

With operating expenses of €7.167 million, the net impact of income and expenditure is a net profit of €27,000.
Statement of income and expenditure for 2016*

ALL FIGURES ARE GIVEN IN THOUSANDS OF EUROS.

REVENUE

- Registrations: 2,684
- Exhibition: 2,281
- Advertising / sponsorship: 374
- Membership: 491
- Corporate membership: 144
- Elsevier royalties / commission: 649
- Other revenue: 618

TOTAL: 7,241

EXPENDITURE  absolute value

- Venue: 815
- Technical equipment: 755
- Promotion and communication: 197
- Catering: 556
- Scientific educational programme and committees: 763
- Payroll charges: 2,620
- General and administration: 666
- Elsevier charges: 298
- Other expenditure: 497

TOTAL: 7,167

FINANCIAL RESULT

- Financial income: 7
- Bank and credit card charges: -47
- Other financial charges: -7

TOTAL: -47

NET RESULT (NET PROFIT) 27

* These figures are for 2016. At the time of writing, the figures for 2017 are being audited and the final results will be presented for approval at ESTRO 37.
Treasurer’s report for 2017

On the left page you can see a short summary of the audited figures for 2016, showing a net profit of €27,000. Turning to 2017, the aim of the budget was again to maintain a positive buffer of €186,000 on a total turnover exceeding €7,800,000. This reflects our philosophy that revenue is to be re-invested into the Society creating benefits and services for our members and stakeholders.

At the time of writing, the figures for 2017 are being audited and the final results will be presented for approval at the general assembly during our annual meeting – ESTRO 37 in Barcelona, Spain. Revenues and expenses at the end of 2017 are estimated at €8,300,000 and -€8,252,000 respectively, yielding (including the financial and extraordinary results) a modest estimated net profit of €48,000.

Looking back at last year, it has again been confirmed that the ESTRO annual meeting represents approximately 50% of the total revenue, with the technical exhibition being a major contribution. We can also see a steady increase in institutional membership, with 45 institutions in 2017 (five more than in 2016).

The defensive profile for the management of the ESTRO reserves proved to be beneficial again in safeguarding our capital (exceeding €2,100,000) within the turbulent financial market of 2017. For 2017, this management strategy resulted in an annual return of investment of approximately 2.2% (2.9% in 2016).

Please feel free to contact me at any time with questions or concerns regarding ESTRO’s financial situation, and of course, I look forward to meeting you all at our annual conference in Barcelona.

Warm regards,

Dirk Verellen
ESTRO Treasurer
### 1. Committees (for 2017)

#### Board of directors
Yolande Lievens (Belgium), *President*
Philip Poortmans (France), *Past-President*
Umberto Ricardi (Italy), *President-Elect*
Dirk Verellen (Belgium), *Treasurer*
Laura Mullaney (Ireland), *Board member*
Claudio Fiorino (Italy), *Board member*
Matthias Guckenberger, (Switzerland), *Board member*
Håkan Nyström (Sweden), *Board member*
Peter Hoskin (UK), *Board member*
Marianne Nordsmark (Denmark), *Board member*
Conchita Vens (The Netherlands), *Board member*

#### Executive council
Yolande Lievens (Belgium), *President*
Umberto Ricardi (Italy), *President-Elect*
Philip Poortmans (The Netherlands), *Past-President*
Dirk Verellen (Belgium), *Treasurer*
Alessandro Cortese (Belgium), *ESTRO Chief Executive Officer*

#### Nominating council
Yolande Lievens (Belgium), *President*
Umberto Ricardi (Italy), *President-Elect*
Philip Poortmans (The Netherlands), *Past-President*

#### Stakeholder council
Yolande Lievens (Belgium), *President*
Umberto Ricardi (Italy), *President-Elect*
Philip Poortmans (The Netherlands), *Past-President*

#### Scientific council
Yolande Lievens (Belgium), *President*
Umberto Ricardi (Italy), *President-Elect*
Philip Poortmans (The Netherlands), *Past-President*
Michael Baumann (Germany), *Editor-in-Chief (Radiotherapy & Oncology)*
Ludvig Muren (Denmark), *Editor-in-Chief (phiRO)*
Marianne Nordsmark (Denmark), *Board representative*
Matthias Guckenberger (Switzerland), *Board representative*
Conchita Vens (The Netherlands), *Board representative*
Claudio Fiorino (Italy), *Board representative*
Håkan Nyström (Sweden), *Board representative*
Claus Belka (Germany), *ACROP committee chair*
Daniel Zips (Germany), *Co-Editor-in-Chief ctRO & clinical committee chair*
Jesper Eriksen (Denmark), *education council chair*
Christian Kirisits (Austria), *GEC-ESTRO committee chair*
Núria Jornet (Spain), *physics committee chair*
Rob Coppes (The Netherlands), *radiobiology committee chair*
Michelle Leech (Ireland), *Co-Editor-in-Chief tipsRO and RTT committee chair*

#### Update:
Ben Slotman (The Netherlands), *elected New ESTRO President in February 2018*

#### Ex-officio
Michael Baumann (Germany), *Editor-in-Chief (Radiotherapy & Oncology)*
Jesper Eriksen (Denmark), *chair of the education council*
Gerben Borst (The Netherlands), yESTRO committee member
Damien Weber (Switzerland), EPTN task force co-chair
Christine Verfaillie (Belgium), Director of Education and Science

Education council (EDC)

Members
Jesper Eriksen (Denmark), chair
Claus Belka (Germany)
Kim Benstead (UK)
Jean-Emmanuel Bibault (France)
Ben Heijmen (The Netherlands)
Peter Hoskin (UK)
Núria Jornet (Spain)
Martijn Kamphuis (The Netherlands)
Michelle Leech (Ireland)
Richard Pötter (Austria)
Umberto Ricardi (Italy)
Sofia Rivera (France)
Viviane Van Egten (Belgium)
Christine Verfaillie (Belgium)
Marie-Catherine Vozenin (Switzerland)
Eduardo Zubizaretta (Austria)

Programme leaders
Jesper Eriksen (Denmark), chair EDC - leader live programme
Kim Benstead (UK), leader CCUEMS/fellows/examination programme

Michelle Leech (Ireland), leader blended learning programme
Richard Pötter (Austria), leader intercontinental education programme
Christine Verfaillie (Belgium), leader pedagogic programme
Marie-Catherine Vozenin (Switzerland), leader mobility programme

Standing committees

Clinical committee
Daniel Zips (Germany), chair
Gerben Borst (The Netherlands)
Corinne Faivre-Finn (UK)
Karina Haustermans (Belgium)
Morten Hoyer (Denmark)
Joanna Kazmierska (Poland)
Mechthild Krause (Germany)
Pedo Lara (Spain)
Eric Lartigau (France)
Yolande Lievens (Belgium)
Lorenzo Livì (Italy)
Corrie Marijnen (The Netherlands)
Claus Rödel (Germany)

GEC-ESTRO brachytherapy committee
Christian Kirisits (Austria), chair
Bradley Pieters (The Netherlands), chair-elect
Jacob Lindegaard (Denmark), past-chair
Taran Hellebust (Norway)
Arthur sun Myint (UK)
Frank-André Siebert (Germany), chair brachytherapy

Vratislav Strnad (Germany), chair breast
Kari Tanderup (Denmark), chair gynaecology
György Kovács (Germany), chair head & neck
Li Tee Tan (UK), chair brachy-HERO
Peter Hoskin (UK), chair UroGEC
Csbar Polgar (Hungary)
Cyrius Chargari (France), observer yESTRO committee

GEC-ESTRO advisory board
Christian Kirisits (Austria), chair
Dimos Baltas (Germany)
Johannes Dimopoulos (Greece)
Beth Erickson (USA)
Ina Jürgenliemk-Schulz (The Netherlands)
Jose Perez-Calatayud (Spain)
Tibor Major (Hungary)
Umesh Mahantshetty (India)
Janusz Skowronek (Poland)
Frank Verhaegen (The Netherlands)

Physics committee
Núria Jornet Sala (Spain), chair
Robin Garcia (France), secretary
Catharine Clark (UK)
Claudio Fiorino (Italy)
Dietmar Georg (Austria)
Eduard Gershkevitsh (Estonia)
Ben Heijmen (The Netherlands)
Marco Schwarz (Italy)
Frank-André Siebert (Germany)
Daniela Thorwarth (Germany), observer yESTRO committee
Wouter van Elempt (The Netherlands), observer yESTRO committee
Dirk Verellen (Belgium)
Ludvig Muren (Denmark), observer - Editor-in-Chief phiRO
David Thwaites (Australia), observer, Radiation & Oncology, physics editor

RTT (Radiation Therapist) committee
Michelle Leech (Ireland), chair
Bartosz Bak (Poland)
Annette Bojen (Denmark)
Ilija Curic (Serbia)
Aileen Duffton (UK)
Martijn Kamphuis (The Netherlands)
Isabel Lobato (Portugal)
Laura Mullaney (Ireland), observer young task force
Philipp Scherer (Austria)
Yat Man Tsang (UK)

Radiobiology committee
Rob Coppes (The Netherlands), chair
Jan Bussink (The Netherlands)
Anthony Chalmers (UK)
Nils Cordes (Germany)
Cihan Gani (Germany)
Anne Kiltie (UK)
Laura Marignol (Ireland)
Peter Van Luijk (The Netherlands)
Conchita Vens (The Netherlands)

Young ESTRO committee
Jean-Emmanuel Bibault (France), clinical young ESTRO co-chair
Pierfrancesco Franco (Italy), clinical young ESTRO co-chair
Martin-Inmanuel Bittner (UK), clinical/radiobiology
Cyrus Chargari (France), clinical/radiobiology
Gerben Borst (The Netherlands), clinical
Ludwig Dubois (The Netherlands), radiobiology
Laura Mullaney (Ireland), RTT
Kathrine Roe Redalen (Norway), physics
Mateusz Spałek (Poland), clinical
Daniela Thorwarth (Germany), physics
Wouter van Elempt (The Netherlands), physics

Advisory Committee on Radiation Oncology Practice (ACROP)
Claus Belka (Germany), chair
Daniel Zips (Germany), clinical committee
Eric Larigau (France), clinical committee
György Kovacs (Germany), GEC-ESTRO committee
Jose Perez-Calatayud (Spain), GEC-ESTRO committee
Brendan McClean (Ireland), physics committee
Eduard Gershkevitch (Estonia), physics committee
Rob Coppes (The Netherlands), radiobiology committee

Jan Bussink (The Netherlands), radiobiology committee
Philip Scherer (Austria), RTT committee
Mirjam Mast (The Netherlands), RTT committee
Richard Pötter (Austria), education council
Jesper Grau Eriksen (Denmark), chair education council
Mateusz Spałek (Poland), observer

National societies committee
Umberto Ricardi (Italy), chair
Núria Jornet (Spain), education & training committee
Panos Papagiannis (Greece), GEC-ESTRO committee
Robin Garcia (France), physics committee
Annette Bojen (Denmark), RTT committee
Bartosz Bak (Poland), RTT committee
Jean-Emmanuel Bibault (France), young committee
Maia Dzhugashvili (Spain)
Filipe Moura (Portugal), ACROP
Daniel Zips (Germany), clinical committee

Radiation oncology safety and quality committee (ROSQC)
Mary Coffey (Ireland), RTT
Wolfgang Doerr (Austria), radiobiologist
Tommy Knöös (Sweden), physicist
Dirk Verellen (Belgium), *physicist*
Eric Lartigau (France), *radiation oncologist*
Anita O’Donovan (Ireland), *RTT*
Julian Malicki (Poland), *radiation oncologist*
Edward Naessens (Ireland), *patient representative*
Todd Pawlicki (USA), *physicist*
Petra Reijnders (The Netherlands), *patient safety manager*

**Task force: European Particle Therapy Network (EPTN)**

**Co-chairs**
Cai Grau (Denmark)
Damien Weber (Switzerland)

**Clinical coordinators**
Hans Langendijk (The Netherlands), *leader*
Roberto Orecchia (Italy)
Karin Hausterman (Belgium)
Cai Grau (Denmark)
Daniel Zips (Germany)
Jacques Balosso (France)
Esther Troost (Germany)

**Dose assessment, quality assurance, dummy runs, technology inventory**
Oliver Jäckel (Germany)
Sairos Safai (Switzerland)
Stefan Menkel (Germany)

**Education**
Morten Høyer (Denmark)
Marco Schwarz (Italy)

**Image guidance in particle therapy**
Aswin Hoffmann (Germany)
Alessandra Bolsi (Switzerland)

**TPS in particle therapy**
Håkan Nyström (Sweden)
Tony Lomax (Switzerland)

**Radiobiology, RBE**
Manjit Dosanjh (Switzerland)
Bleddyn Jones (UK)
Jörg Pawelke (Germany)
Martin Prutschy (Switzerland)
Brita S. Sørensen (Denmark)

**Health economy**
Ulrike L. Kliebsch (Switzerland)
Yolande Lievens (Belgium)
Klaus Nagels (Germany)

**HERO group**
Cai Grau (Denmark), *co-chair*
Yolande Lievens (Belgium), *co-chair*
Josep Borras (Spain)
Mary Coffey (Ireland)
Peter Dunscombe † (Canada)
Lionel Perrier (France)
Judith van Loon (The Netherlands)
Noémie Defourny (Belgium)
2. Office (updated in March 2018)

### Senior management team

- **Alessandro Cortese**, chief executive officer

### Strategic programmes delivery

- **Sven Bossu**, innovation managing director
- **Chiara Gasparotto**, policy & partnerships director
- **Christine Verfaillie**, education & science managing director

### Organisation delivery

- **Nathalie Cnops**, senior HR manager
- **Arnaud Ponsart**, finance manager

### Staff

- **Dina Ardiana**, HR and finance coordinator
- **Gabriella Axelsson**, public affairs project manager
- **Eralda Azizaj**, scientific programme manager
- **Agostino Barrasso**, congress manager
- **Mickaël Bohland**, IT development manager
- **Evelyn Chimfwembe**, society affairs and research projects manager
- **Benjamin Corroy**, IT support officer
- **Valérie Cremades**, corporate relations manager
- **Noémie Defourny**, health economics specialist
- **Luis Ferreira Teixeira**, project manager
- **Elena Giusti**, project manager
- **Carolina Goradesky**, events project manager
- **Rebecca Hansmann**, ESTRO programmes & office administrator
- **Cécile Hardon-Villard**, communications manager
- **Sigrid Jacobs**, ESTRO programmes supervisor
- **Marta Jayes**, governance affairs project manager
- **Laura la Porta**, education & science project manager
- **Arta Leci**, ESTRO Cancer Foundation Coordinator
- **Myriam Lybeer**, membership manager
- **Michela Mizzi**, communication coordinator
- **Maria Nankova**, scientific programme administrator
- **Alessandra Nappa**, project manager
- **Lilian Niwerungero**, ESTRO programmes administrator
- **Miika Palmu**, project manager
- **Essi Saarto**, scientific programme coordinator
- **Claire Thomas**, ESTRO programmes administrator
- **Gurkan Ulusoy**, accounting coordinator
- **Melissa Vanderijst**, marketing project manager
- **Viviane van Egten**, education manager

### Consultants:

- **Mieke Akkers**, project manager
- **Daneel Bogaerts**, graphic designer
- **Sophie Nelis**, graphic designer
2017 CORPORATE MEMBERS

Gold corporate members

Accuray International
CIVCO Radiotherapy
Elekta
IBA
Orfit Industries NV
Qfix
Royal Philips
Siemens Healthcare GmbH
Varian Medical Systems International AG

Corporate members

Aquilab
Brainlab
Carl Zeiss Meditec AG
C-RAD Positioning AB
Eckert & Ziegler BEBIG SA
humediQ global GmbH
IntraOp Medical Corporation
Klarity Medical & Equipment Co., Ltd
LAP GmbH Laser Applikationen
MacroMedics BV
Mevion Medical Systems
MIM Software Inc
Mirada Medical Ltd
Mobius Medical Systems LP
NELCO Ltd
PTW
RaySearch Laboratories AB
Standard Imaging Inc
Sun Nuclear Corporation
Virtual Ltd
Vision RT Ltd

Scientific and educational sponsors

Accuray International
Elekta
Elsevier
University of Wisconsin
Varian Medical Systems International AG

2017 JOINT MEMBERSHIPS

Joint membership agreements with European young national societies

Young Italian Association of Oncological Radiotherapy (AIRO GIOVANI)
Israeli Society for Clinical Oncology and Radiotherapy (ISCORT)
Belgian Society for Radiation Oncology (BVRO/ABRO)
Spanish Society for Radiotherapy and Oncology (SEOR)
Young Romanian Radiation Oncologists Group (YRROG)

Joint membership agreements with non-European national/regional societies

Canadian Association of Radiation Oncology (CARO)
Iranian Society of Clinical Oncology (ISCO)
Japanese Society for Radiation Oncology (JASTRO)
Korean Society for Radiation Oncology (KOSRO)
The Royal Australian and New Zealand College of Radiologists (RANZCR)
The South East Asian Radiation Oncology Group (SEAROG)
2017 INSTITUTIONAL MEMBERS

Austria
Medical University of Vienna

Belgium
AZ Turnhout
CHU Liège
GZA Ziekenhuizen, Sint Augustinus – Iridium
Kankernetwerk Antwerpen
Institut Jules Bordet
University Hospital Gasthuisberg (UZ Leuven)
Universitair Ziekenhuis Brussel

Czech Republic
University Hospital Hradec Kralove

Denmark
Aalborg University Hospital
Naestved Hospital
Odense University Hospital

Estonia
North Estonian Regional Hospital Cancer Center

France
Centre Oscar Lambret
GORTEC – CHU Bretonneau – CORAD
Institut Gustave Roussy

Germany
Gemeinschaftspraxis fuer Strahlentherapie Singen-Friedrichshafen
Klinikum rechts der Isar, TU Munich

L.-Maximilians-Univ., KI Grosshadern (Munich)
University Hospital of Tübingen

Hungary
University of Szeged

Italy
AOU Careggi – University of Florence
A.O. Spedali Civili di Brescia – Istituto del Radio O. Alberti
Fondazione IRCCS Istituto Nazionale Tumori
Humanitas Cancer Centre
Ospedale Santa Maria della Misericordia (Perugia)
Università Cattolica de Sacro Cuore

The Netherlands
Leiden University Medical Centre
MAASTRO
NKI – Netherlands Cancer Institute
Radboud University Medical Centre
Radiotherapiegrou (Deventer)
UMC Utrecht

Poland
Greater Poland Cancer Centre

Portugal
Champalimaud Cancer Centre

Romania
Regional Institute of Oncology Iasi

Spain
Fundacio IMOR

Sweden
Karolinska University Hospital

Switzerland
Centre Hospitalier Universitaire Vaudois – CHUV
Ente Ospedaliero Cantonale in Bellinzona
Luzerner Kantonsspital
University Hospital Zürich

UK
Altnagelvin Hospital, Western Health & Social Care Trust
The Institute of Cancer Research (Surrey)
St Bartholomew’s Hospital
**EDITORIAL TEAMS OF ESTRO PUBLICATIONS**

### 1. Radiotherapy & Oncology

**Editor-in-Chief**  
Michael Baumann, Germany

**Editor-in-Chief Emeritus**  
Jens Overgaard, Denmark

**Editors**  
Raymond Abratt, South Africa  
Markus Alber, Denmark  
Jan Alsnér, Denmark  
Michael Baumann, Germany  
Michel Bolla, France  
Thomas Bortfeld, USA  
Jean Bourhis, France  
Michael Brada, UK  
Robert Bristow, Canada  
Wilfried Budach, Germany  
Jan Bussink, The Netherlands  
Felipe Calvo, Spain  
Stephanie Combs, Germany  
Rob Coppes, The Netherlands  
Nils Cordes, Germany  
Olav Dahl, Norway  
Dirk De Ruyscher, The Netherlands  
Joseph Deasy, USA  
Jørgen Debus, Germany  
Jim Denham, Australia  
Eric Deutsch, France  
Wolfgang Dörr, Austria  
Gillian Duchesne, Australia  
Avraham Eisbruch, USA  
Sara Faithfull, UK  
Claudio Fiorino, Italy  
Dietmar Georg, Austria  
Daniel Richard Gomez, USA  
Cai Grau, Denmark  
Vincent Gregoire, Belgium  
Anca-Ligia Grosu, Germany  
Matthias Guckenberger, Switzerland  
Kevin Harrington, UK  
Karin Haustermans, Belgium  
Ben J Heijmen, The Netherlands  
Masahiro Hiraoka, Japan  
Peter Hoskin, UK  
Johannes Kaanders, The Netherlands  
Joanna Kazmierska, Poland  
Lucyna Kępka, Poland  
Tommy Knöös, Sweden  
Mechthild Krause, Germany  
Tomas Kron, Australia  
Philippe Lambin, The Netherlands  
Johannes Langendijk, The Netherlands  
Eric Lartigau, France  
Anne W M Lee, China  
Michelle Leech, Ireland  
Zhongxing Liao, USA  
Steffen Löck, Germany  
Philippe Maingon, France  
Ben Mijnheer, The Netherlands  
Ludvig Muren, Denmark  
Ursula Nestle, Germany  
Birgitte Offersen, Denmark  
Dag Rune Olsen, Norway  
Jens Overgaard, Denmark  
Philip Poortmans, The Netherlands  
Richard Pötter, Austria  
Dirk Rades, Germany  
Hans Peter Rodemann, Germany  
Francisco Sanchez-Doblado, Spain  
Herman Suit, USA  
Howard Thames, USA  
Daniela Thorwarth, Germany  
David Thwaites, UK  
Wolfgang Tome, USA  
Vincenzo Valentini, Italy  
Uulke van der Heide, The Netherlands  
Albert van der Kogel, USA  
Conchita Vens, The Netherlands  
Marcel Verheij, The Netherlands  
Marcel Verheij, The Netherlands  
Dirk Vordermark, Germany  
Henning Willers, USA  
Bradly Wouters, Canada  
Zhen Zhang, China  
Daniel Zips, Germany

**Past editors**  
Emmanuel van der Schueren  
Harry Bartelink
# 2. Clinical & Translational Radiation Oncology (ctRO)

<table>
<thead>
<tr>
<th>Editors-in-Chief</th>
<th>Editorial board members</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Pierre Blanchard, France</td>
<td>Jean-Emmanuel Bibault, France</td>
<td>Andre Dekker, The</td>
</tr>
<tr>
<td>Daniel Zips, Germany</td>
<td>Gerben Borst, Netherlands</td>
<td>Netherlands</td>
</tr>
<tr>
<td></td>
<td>Joe Butler, UK</td>
<td>Dan Duda, USA</td>
</tr>
<tr>
<td></td>
<td>Anthony Chalmers, UK</td>
<td>Emmanouil Fokas, Germany</td>
</tr>
<tr>
<td></td>
<td>Gilles Créhange, France</td>
<td>Steven J. Frank, USA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maria Antonietta Gambacorta, Italy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cihan Gani, Germany</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Stephen Hahn, USA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Morten Hoyer, Denmark</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sofie Isebaert, Belgium</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Joanna Kazmierska, Poland</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anna Kirby, UK</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anne Laprie, France</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pedro C. Lara, Spain</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cécile Le Péchoux , France</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lorenzo Livi, Italy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Brian O'Sullivan, Canada</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maximilian Schmid, Austria</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Esther Troost, Germany</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Yu Xiaoli, China</td>
</tr>
</tbody>
</table>

# 3. Physics & Imaging in Radiation Oncology (phiRO)

<table>
<thead>
<tr>
<th>Editor-in-Chief</th>
<th>Editorial board members</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Ludvig Muren, Denmark</td>
<td>Raffaella Basilico, Italy</td>
<td>Peter Greer, Australia</td>
</tr>
<tr>
<td></td>
<td>Tobias Bäuerle, Germany</td>
<td>Anca-Ligia Grosu, Germany</td>
</tr>
<tr>
<td></td>
<td>Jan Bussink, The Netherlands</td>
<td>Nuria Jornet Sala, Spain</td>
</tr>
<tr>
<td></td>
<td>Catharine Clark, UK</td>
<td>Christian Kirisits, Austria</td>
</tr>
<tr>
<td></td>
<td>Luca Cozzi, Italy</td>
<td>Tomas Kron, Australia</td>
</tr>
<tr>
<td></td>
<td>Paul Crabtree, UK</td>
<td>Monique Maas, The</td>
</tr>
<tr>
<td></td>
<td>Claudio Fiorino, Italy</td>
<td>Netherlands</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Eirik Malinen, Norway</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lorenzo Mannelli</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Laura Martincich, Italy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vitali Moiseenko, USA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Evis Sala, USA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Marco Schwarz, Italy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jan-Jakob Sonke, The</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Netherlands</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Uulke van der Heide, The</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Netherlands</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wouter van Elmpt, The</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Netherlands</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dirk Verellen, Belgium</td>
</tr>
</tbody>
</table>

# 4. Technical Innovations & Patient Support in Radiation Oncology (tipsRO)

<table>
<thead>
<tr>
<th>Editors-in-Chief</th>
<th>Editorial board members</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Sara Faithfull, UK</td>
<td>Nicolaus Andratschke, Switzerland</td>
<td>Mary Coffey, Ireland</td>
</tr>
<tr>
<td>Michelle Leech, Ireland</td>
<td>Annette Bøjen, Denmark</td>
<td>Berardino De Bari, France</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Geoffrey P Delaney, Australia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Colleen Dickie, Canada</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Nicola Dinapoli, Italy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ed Field, UK</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Suneil Jain, UK</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sultan Kav, Turkey</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mirjam Mast, The Netherlands</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Philipp Scherer, Austria</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Suzanne van Beek, The</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Netherlands</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sharon Wong Mei Mei, Singapore</td>
</tr>
</tbody>
</table>
5. ESTRO Newsletter

Corners editors
Esther Bloemen-Van Gurp
Åsa Carlsson Tedgren
Ilija Ćurić
Dirk De Ruyscher
Aileen Duffton
Peter Dunscombe †
Jesper Eriksen
Pierfrancesco Franco

Mischa Hoogeman
Peter Hoskin
Robert Hudej
Madelon Johannesma
Hans Kaanders
Philippe Lambin
Yolande Lievens
Isabel Lobato
Brendan Mclean

Bradley Pieters
Christian Richter
Kathrine Røe Redalen
Philipp Scherer
Kari Tanderup
Christine Verfaillie
Marie-Catherine Vozenin

HERO PUBLICATIONS


AWARDS GRANTED AT ESTRO 36

Lifetime achievement awards
Annette bøjen (Denmark)  
Alan Nahum (UK)  
Jens Overgaard (Denmark)  
Hans-Peter Rodemann (Germany)  
Paul Van Houtte (Belgium)

ESTRO award lectures
Emmanuel van der Schueren Award Lecture  
Substantial and ‘for free’ improvement of radiotherapy practice in high and low income countries  
Ben Heijmen (The Netherlands)

Iridium Award
Brachytherapy physics developments: look back in anger, grateful, and with hope  
Jack Venselaar (The Netherlands)

Jens Overgaard Legacy Award
Individual patient data meta-analysis in head and neck cancer: an international and multidisciplinary collaboration  
Pierre Blanchard (France)  
Jean Bourhis (Switzerland)  
Jean-Pierre Pignon (France)

Regaud Award
More than a century after the serendipitous discovery of X-rays, there is still a bright future for radiation oncology…  
Jean Bourhis (Switzerland)

Donal Hollywood Award
In vitro prediction of DNA repair defects reveals association with poor clinical outcome in HNSCC  
Paul Essers (The Netherlands)

Klaas Breur Award
The 5 R(elevant) principles of radiotherapy in multimodal cancer treatment  
Claus Rödel (Germany)

Academic award
Jack Fowler University of Wisconsin Award  
Dosimetric quantification of the ‘true’ ano-inguinal lymphatic drainage of anal cancer patients  
Hendrik Dapper (Germany)

Honorary member award lectures
Optimising the treatment of HPV-related oropharyngeal cancer: the difficult journey back  
Brian O’Sullivan (Canada)

Potential of radiation therapy to convert the tumor into an in situ vaccine  
Silvia Formenti (USA)

Quality improvement in radiotherapy: history, significance and impact of dosimetry audits  
Joanna Jzewska (Austria)

Honorary physics award
Cognitive perspective in the radiation oncology physics domain  
Vincenzo Valentini (Italy)

Company award lectures
ESTRO-Varian Award  
Tarjectory Optimization in Radiotherapy Using Sectioning (TORUS)  
Christopher Locke (USA)

ESTRO-Accuray Award  
Limited interfractional variability of respiration-induced tumor motion in esophageal cancer RT  
Peng Jin (The Netherlands)

ESTRO-Elekta Brachytherapy Award  
Testing and MR-compatible afterloader for MR-based source tracking in MRI-guided HDR brachytherapy  
Ellis Beld (The Netherlands)

GEC-ESTRO Best Junior Presentation Elekta Award  
Sponsored by Elekta  
Brachytherapy

Improved class solutions for prostate brachytherapy planning via evolutionary machine learning  
Stefanus Maree (The Netherlands)
ABBREVIATIONS

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAPM</td>
<td>American Association of Physicists in Medicine</td>
</tr>
<tr>
<td>ABC</td>
<td>Advanced Breast Cancer</td>
</tr>
<tr>
<td>ABRO-BVRO</td>
<td>Belgian Society of Oncological Radiotherapy</td>
</tr>
<tr>
<td>ACROP</td>
<td>Advisory Committee on Radiation Oncology Practice</td>
</tr>
<tr>
<td>AIRO GIOVANI</td>
<td>Young Italian Radiation Oncology Society</td>
</tr>
<tr>
<td>APAC</td>
<td>Asia Pacific Advisory Committee</td>
</tr>
<tr>
<td>ARTFORCE</td>
<td>Adaptive and innovative Radiation Treatment FOR improving Cancer patients’ treatment outcome</td>
</tr>
<tr>
<td>ASCO</td>
<td>American Society of Clinical Oncology</td>
</tr>
<tr>
<td>ASN</td>
<td>Autorité de sûreté nucléaire</td>
</tr>
<tr>
<td>BIR</td>
<td>The British Institute of Radiology</td>
</tr>
<tr>
<td>CARO</td>
<td>Canadian Association for Radiation Oncology</td>
</tr>
<tr>
<td>CANMEDS</td>
<td>The Royal College of Physicians and Surgeons of Canada</td>
</tr>
<tr>
<td>CERN</td>
<td>Conseil Européen pour la Recherche Nucléaire</td>
</tr>
<tr>
<td>CCORE</td>
<td>Collaboration for Cancer Outcomes, Research and Evaluation</td>
</tr>
<tr>
<td>CCUEMS</td>
<td>Core Curriculum European Union of Medical Specialists</td>
</tr>
<tr>
<td>CERRO</td>
<td>Clinical and Experimental Research in Radiation Oncology</td>
</tr>
<tr>
<td>CME</td>
<td>Continued Medical Education</td>
</tr>
<tr>
<td>COCIR</td>
<td>European Coordination Committee of the Radiological, Electromedical and Healthcare IT Industry</td>
</tr>
<tr>
<td>ctRO</td>
<td>Clinical and Translational Radiation Oncology</td>
</tr>
<tr>
<td>DOVE</td>
<td>Dynamic Oncology Virtual ESTRO</td>
</tr>
<tr>
<td>EACCME</td>
<td>European Accreditation Council for Continuing Medical Education</td>
</tr>
<tr>
<td>EANM</td>
<td>European Association of Nuclear Medicine</td>
</tr>
<tr>
<td>EAPM</td>
<td>European Alliance for Personalised Medicine</td>
</tr>
<tr>
<td>EAU</td>
<td>European Association of Urology</td>
</tr>
<tr>
<td>ECC</td>
<td>European Cancer Congress</td>
</tr>
<tr>
<td>ECCO</td>
<td>European CanCer Organisation</td>
</tr>
<tr>
<td>ECF</td>
<td>ESTRO Cancer Foundation</td>
</tr>
<tr>
<td>ECPC</td>
<td>European Cancer Patient Coalition</td>
</tr>
<tr>
<td>EDC</td>
<td>Education Council</td>
</tr>
<tr>
<td>EFOMP</td>
<td>European Federation of Organisations in Medical Physics</td>
</tr>
<tr>
<td>EHNS</td>
<td>European Head and Neck Society</td>
</tr>
<tr>
<td>EIBIR</td>
<td>European Institute for Biomedical Imaging Research</td>
</tr>
<tr>
<td>ELCC</td>
<td>European Lung Cancer Conference</td>
</tr>
<tr>
<td>EMUC</td>
<td>European Multidisciplinary meeting on Urological Cancers</td>
</tr>
<tr>
<td>EORTC</td>
<td>European Organisation for Research and Treatment of Cancer</td>
</tr>
<tr>
<td>EPTN</td>
<td>European Particle Therapy Network</td>
</tr>
<tr>
<td>ESGO</td>
<td>European Society of Gynaecological Oncology</td>
</tr>
<tr>
<td>ESPO</td>
<td>European Society for Medical Oncology</td>
</tr>
<tr>
<td>ESP</td>
<td>European Society of Pathology</td>
</tr>
<tr>
<td>ESR</td>
<td>European Society of Radiology</td>
</tr>
<tr>
<td>ERPW</td>
<td>European radiological protection research week</td>
</tr>
</tbody>
</table>
ANNEX
Targeting optimal care, together